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 The detrimental impact of psychosis on individuals and society has sparked 
interest in early detection and intervention strategies to improve outcomes for those who 
are high-risk for developing psychosis. This study used data collected by the Recognition 
and Prevention (RAP) program to explore the progression of Axis I and Axis II disorders, 
clinical and functional characteristics, and predictors of conversion in a Clinical High 
Risk (CHR) sample. Using the RAP Program’s classification system, participants were 
assigned to the following subgroups based on symptom presentation: Clinical High Risk 
Positive (CHR+) which is defined by the presence of attenuated positive symptoms and 
Clinical High Risk Negative (CHR-) which requires the presence of attenuated negative 
symptoms.  
Participants consisted of 156 subjects (110 males and 46 females) who 
participated in the RAP Program during Phase I (2000-2006) and were separated into the 
high-risk groups: CHR+ and CHR-.  These results indicated that Axis I disorders (mood, 
anxiety, substance use, and attention-deficit and disruptive behavior disorders) presented 
similarly at baseline in the CHR subgroups, however there were significant differences in 
the prevalence rates of paranoid personality disorder, borderline personality disorder, and 
schizoid personality disorder. In exploring the relationships between psychiatric 
 
 
disorders, attenuated symptoms, and functioning, it was found that lower levels of role 
functioning were associated with mood disorders for CHR- participants.  Additionally, 
social functioning and attenuated negative symptoms were found to have an impact on 
Cluster A personality presentation in both CHR subgroups. This study also explored the 
progression of psychiatric disorders, and results demonstrated that mood, anxiety, 
attention-deficit and disruptive behavior disorders, and personality disorders were 
persistent and recurrent from baseline to follow-up in both subgroups. Additionally, in 
examining predictors of conversion, positive symptoms were found to be the strongest 
predictor of conversion to psychosis and mood disorders were found to be a significant 
predictor of non-conversion.  
The results from this study convey that CHR adolescents present with a 
constellation of diagnoses and symptoms. The findings suggest that it may be beneficial 
to continue to screen individuals diagnostically to develop specific intervention strategies 
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Chapter 1: Introduction 
 
This dissertation contributes to an area of research that focuses on individuals 
who are clinical high risk (CHR) for developing psychosis. Specifically, this study will 
use data collected by the Recognition and Prevention (RAP) Program, a longstanding 
CHR Program in New York, to examine the baseline prevalence rates of co-occurring 
psychiatric disorders in a high-risk population and clinical and functional characteristics. 
Additionally, this study will explore which baseline characteristics predict conversion to 
psychosis and assess the long-term stability of psychiatric disorders in individuals who 
are at CHR in this cohort.  The outcomes of these analyses may have important 
implications for prevention and/or treatment for high-risk populations.  
Rationale and Significance     
There has been emerging interest in the early detection and prevention of 
psychosis, in particular schizophrenia. There is considerable research demonstrating the 
debilitating effects of psychosis and the detrimental impact it has on an individual’s 
quality of life. Individuals suffering from psychosis often experience cognitive 
difficulties, difficulties in maintaining interpersonal relationships, and role functioning 
problems such as academic and employment difficulties (Barch & Sheffield, 2014; de 
Waal, Dixon, & Humensky, 2018; Karambelas et al., 2018; McCann, Lubman, & Clark, 
2011; Redmond, Larkin, & Harrop, 2010; Schaefer, Giangrande, Weinberger  & 
Dickinson, 2013; Sheffield,  Karcher, & Barch, 2018; Tolman  & Kurtz, 2012). 
Unfortunately, this population is also susceptible to high mortality rates due to physical 
health problems and high rates of suicide (Castagnini & Bertelsen, 2011; Henderson,et 
al., 2015; Pompili et al., 2011; Suvisaari, et al., 2010). Due to these poor outcomes, over 
2 
 
the past twenty years there has been interest in prevention and developing criteria to 
identify individuals in this pre-psychotic phase of illness., as this may provide a window 
of opportunity for intervention. Terms such as “at risk”, “ high-risk”, “clinical high risk”, 
“ultra high risk”, and “prodromal” are used to categorize individuals in this phase in the 
ever growing literature on the subject.   
Extensive research on the potential negative long-term outcomes of psychosis has 
propelled the prevention movement to gain momentum, calling for early intervention to 
begin as soon as possible, before psychosis becomes particularly disruptive to social, 
academic, and occupational functioning (McGorry, Killackey, & Yung, 2008). By 
targeting individuals who are at-risk for developing psychosis, we may be better able to 
identify factors that predict conversion to psychosis, which could in turn help to more 
readily inform early intervention strategies. Interest in early intervention research has led 
to the development of reliable and valid instruments which are used to identify 
individuals who are high-risk for developing psychosis. Many high-risk studies over the 
last several decades provided clues about predictors of conversion, and showed rates of 
conversion as high as 50%, with more recent rates between 17% and 35%  (Fusar-Poli et 
al., 2012; Michel, et al., 2018; Miller et al., 2002; Yung et al., 2005). The decline in 
conversion rates may be attributed to false-positives, tailored intervention models, the 
promotion of early intervention programs, and the development of assessment measures 
(Yung and McGorry, 1996; Yung et al., 2007).  
Many studies also suggest that there is a high co-occurrence of nonpsychotic 
disorders in individuals at-risk for psychosis. In fact, most help-seeking individuals cite 
nonpsychotic symptoms such as mood, anxiety, substance use, or behavioral problems as 
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their presenting concern which may overshadow high-risk symptoms (Falkenberg, et al., 
2015; McAusland et al., 2017; Woods et al., 2009).  Given the cooccurrence of other 
psychiatric disorders in this population and declining transition rates to psychotic 
disorders, it is important to investigate how co-occurring disorders impact the outcomes 
of those who do and do not develop psychosis.  
Statement of Purpose  
 Using longitudinal data collected from the Recognition & Prevention (RAP) 
Program at Zucker Hillside Hospital, this study will assess the development of high-risk 
symptoms and potential associations with psychiatric disorders. Furthermore, to better 
understand the impact of psychiatric disorders on prodromal symptomatology and risk for 
conversion to psychosis, this study will assess how these disorders evolve in different 














Chapter 2: Literature Review  
Rationale for Identifying Risk for Psychosis  
Psychotic disorders are mental illnesses which are characterized by impairment in 
perception, emotional experiences, and behavior. Psychotic disorders affect about 3% of 
the population, with the onset typically occurring between the ages of 15 and 25. 
Psychotic disorders include schizophrenia (0.3-0.7%), schizophreniform disorder, 
schizoaffective disorder (0.3%), delusional disorder (0.2%), brief psychotic disorder, and 
other schizophrenia spectrum disorder. Individuals also can meet criteria for psychosis if 
diagnosed with a bipolar or depressive disorder with psychotic features or with a 
diagnosis of substance or medication induced psychosis (American Psychiatric 
Association, 2013). 
Individuals who meet criteria for psychosis vary in their presentation due to their 
own unique combination of symptoms and experiences. Symptoms associated with 
schizophrenia are classified into two categories: positive symptoms and negative 
symptoms. Positive symptoms include hallucinations which are perception-like 
experiences that occur without an external stimulus and delusions which are fixed beliefs 
that are held despite evidence that suggests these beliefs may not be true. These 
symptoms are separate from negative symptoms, which include diminished emotional 
expression, avolition, and anhedonia which could lead to difficulties with attention, 
concentration, social and occupational functioning (American Psychiatric Association, 
2000; Marder & Galderisi, 2017; Tsuang, Glatt, & Faraone, 2011).  
It has been well documented that psychiatric comorbidities are common among 
people with schizophrenia.  According to Buckley et al. (2009), anxiety symptoms are 
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common throughout the course of schizophrenia, with estimated prevalence rates of 15% 
for panic disorder, 29% for posttraumatic stress disorder, and 23% for obsessive 
compulsive disorder. It is also estimated that comorbid depression occurs in 50% of those 
affected by the illness. These nonpsychotic disorders accompanying schizophrenia make 
it challenging to form an accurate clinical picture of individuals who are affected. 
Moreover, it is unclear as to what extent these symptoms solely reflect psychological 
distress or are indeed unique features of a psychotic illness (Buckley et al., 2009). 
There is substantial research to support that attention-deficit and disruptive 
behavior disorders and schizophrenia share similar symptomatology (Brodeur, Kiang, & 
Christensen, 2016; Donev et al., 2011; Niarchou et al., 2018; Oie & Rund, 1999; 
Salomon et al., 2011; Starc et al., 2017). The overlap in symptoms includes impulsivity, 
inattention, impairment in working memory, disorganized behavior, and emotion 
dysregulation, which can impact overall functioning and prognosis over time (Bae et al., 
2010; Jobe & Harrow, 2010; Prouteau et al., 2015). Specifically, for ADHD, adolescents 
who carry this diagnosis are 4.3 times more likely to develop schizophrenia in the future 
in comparison to healthy controls (Dalsgaard et al., 2014). Additionally, externalizing 
behaviors such as conduct disorder are linked to the development of schizophrenia later 
in life (Rubino et al.,2009).  
Individuals with schizophrenia often present with substance use and rates indicate 
that these individuals may engage in substance use at higher rates compared to the 
general population. Substances that are often reported are alcohol, nicotine, and cannabis, 
and opioids. (Khokhar et al., 2018; Winklbaur et al., 2006). As explained by Awad and 
Voruganti (2008), substance use is particularly dominant among individuals suffering 
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from schizophrenia, with approximately 50% meeting diagnostic criteria for a substance 
use disorder at some point in their lives.  In addition, up to 25% of individuals with 
schizophrenia may be actively engaged in substance use at any given time during their 
illness (Awad, &Voruganti, 2012; Buckley & Meyer, 2009). For this population, 
increased substance use is associated with increased hospitalizations and low treatment 
compliance. 
The symptoms and impairments associated with schizophrenia appear to be long-
standing with periods of fluctuation in severity occurring over time (Hersen & Beidel, 
2012). The course of schizophrenia is variable with symptoms wavering in severity and 
intensity (Jones, Hacker, Cormac, Meaden, & Irving, 2012; Perälä  et al., 2007). As 
symptoms become more severe, it may be increasingly more difficult for people to stay in 
touch with reality, maintain relationships, and manage tasks required for daily living 
(Awad & Voruganti, 2012). According to Awad & Voruganti  (2008) the early onset and 
chronic nature of schizophrenia often results in direct  and indirect costs to the 
individuals affected and their family members and caregivers. Individuals affected are 
likely to encounter medical costs for hospital stays, out-patient care, rehabilitation, 
assisted living, and other health professional services. Other difficulties include loss of 
productivity, leading to unemployment. These indirect costs resulting from not being able 
to work can place a toll on these individuals, their families, and society. Caregivers report 
experiencing guilt, worry, shame, and feeling despair for themselves and their affected 
family member (Barker, Lavender, & Morant, 2001). Individuals with schizophrenia may 
also experience emotional suffering, social isolation, emotional distress, depression, and 
even premature death (Lindström, Eberhard, Neovius, & Levander, 2007).  Because of 
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these substantial costs, there has been emerging interest in early detection and 
intervention strategies to alleviate, or if possible, prevent these outcomes. 
Treatment options for schizophrenia include psychiatric medication and 
psychotherapy. Antipsychotic medications such as haloperidol, risperidone, and 
olanzapine have proven to be effective in combination with other therapeutic 
interventions such as such as CBT for psychosis (Dold et al., 2015; Lecomte 2015; 
Olivares, Pinal, & Cinos, 2011). Individual therapy, family therapy, and social skills 
training have also proven to be beneficial (Granholm, Holden, & McQuaid, 2014; 
Haddad, Brain & Scott, 2014). Although these forms of treatment continue to be helpful 
and beneficial for the positive symptoms of schizophrenia, oftentimes, patients are left 
with negative symptoms which account for severe difficulties in functioning and quality 
of life in addition to the costs of treatment such as hospitalization and medication (Patel, 
Cherian, Gohil, & Atkinson, 2014).  Even with optimal treatment, persons with 
schizophrenia often continue to experience substantial impairment throughout much of 
their lives with many struggling with caring for themselves and others (Ofir et al., 2017).  
In addition to the challenges listed above, individuals affected by psychosis are 
also highly stigmatized. The diagnostic label evokes perceptions that individuals with 
psychosis are dangerous, violent, and unpredictable (Corrigan & Kleinlein, 2005; 
Durand-Zaleski, Scott, Rouillon, & Leboyer, 2012). Furthermore, experiences of 
internalization of stigma may occur and can lead to emotional distress in the form of 
depression and anxiety which may have a detrimental impact on recovery, contribute to 
increased shame, and lower treatment adherence (Birchwood et al., 2007; Rusch et al., 
2014). In conclusion, the debilitating effects of psychosis have ushered further 
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exploration of the period before the onset of full-blown psychosis to mitigate adverse 
long-term impact, improve symptoms, and boost functional outcomes.  
The Psychosis Prodrome: A Historical Perspective 
The onset of psychosis varies in length and can be characterized by nonspecific 
changes in thoughts, feelings, behaviors, and functioning. An individual who develops a 
psychotic disorder typically displays symptoms 1-2 years prior to the first psychotic 
break. The time period when symptoms preceding the onset of psychosis are developing 
is referred to as the prodromal period, and typically occurs during late adolescence or 
early adulthood (Häfner et al., 2003). As explained by Salokangas and McGlashan (2008) 
“the prodrome for psychosis is a retrospective concept referring mostly to the period from 
the first noticeable symptoms of unusual experiences to the first prominent psychotic 
symptoms” (p.95). The prodromal period can last several weeks, months or years while 
co-occurring with other disorders and leading to possible functional decline (Larson, 
Walker & Compton, 2010; Woods et al., 2010).  
Presentation of symptoms include attenuated positive symptoms which are not 
severe enough to meet criteria for psychosis and precede full-blown psychosis.  
Prodromal symptoms are deviations in thinking patterns, behavior, and affect. Individuals 
in this phase may present with odd beliefs or unusual behaviors. They may have speech 
that appears vague, overly concrete, or disorganized. Others may note they have 
difficulty holding a conversation. Typically, attention problems, depression, anxiety, 
social difficulties, disorganization, and sleep disturbances emerge first, and then more 
specific attenuated psychotic experiences emerge later. Other common concerns include 
difficulties with memory and low motivation. Individuals may describe experiences 
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where they feel like their thoughts are disappearing, blocked, or coming very rapidly. 
There may be reports that others may know their thoughts possibly accompanied by 
increased suspiciousness. However, these thoughts are not at the intensity of paranoid 
delusions and the disorganized communication does not meet full criteria for a formal 
thought disorder (Goulding et al., 2013).  Individuals may report experiences of others 
watching them, trying to harm them, or feeling fearful without any specific trigger. 
Individuals may also report losing interest in activities, becoming socially withdrawn, 
and displaying less affective expression. Although reports of perceptual experiences and 
ideations may arise, they do not meet the severity of delusions and hallucinations 
(Goulding et al., 2013). Family members, teachers, and others who interact more closely 
with the individual are likely to recognize changes in behavior.  As these symptoms 
occur, individuals are likely to feel confused, frightened, and even doubt their 
experiences. These symptoms may present gradually over several months or years before 
a full onset of psychosis (Larson, Walker, Compton, 2010; Perkins, 2004). These changes 
may also impact a person’s ability to remain focused in school, maintain stable 
employment and relationships, causing distress over time.  
Individuals in the prodromal phase present with psychotic-like experiences which 
are different from full-blown psychosis in that the person questions or doubts their 
experiences. For example, a person may think that someone can read their mind and may 
be uncertain whether or not this experience is real or imaginary. As explained by Kline et 
al. (2012), the difference between psychotic and psychotic-like experiences lies in 
expression of doubt, conviction of reality of the experience. Generally, if these symptoms 
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persist, they may evolve into psychosis but not all psychotic-like experiences are 
predictive of full-blown psychosis.  
To be in the prodromal phase implies that there will be a progression to psychosis. 
Much of the research on the prodrome has relied on retroactive studies, suggesting that 
conversion to psychosis is inevitable. However, there is ample research to suggest that 
the majority of help-seeking individuals do not go on to develop psychosis (Cannon et al., 
2008; Cornblatt et al., 2003; Yung et al., 2004). Also, prodromal symptomatology is  not 
just related to psychotic symptoms and can be non-specific, further highlighting that the 
presence of prodromal symptoms does not subsequently indicate conversion to psychosis. 
To reconcile this discrepancy, there has been a shift in the research field to replace the 
term prodrome with other terminology such as at-risk, high-risk, clinical high risk, and 
ultra high risk to accurately capture the vulnerability rather than imminency of psychosis 
(Fusar-Poli et al., 2013).  
Conceptualizing the High-Risk Stage  
 In the last couple decades, there has been a considerable shift to understand the 
complexity and course of psychosis which has led to several advancements such as 
reliable and structured instruments to identify individuals at-risk, longitudinal studies to 
identify mechanisms and functional outcomes, and therapeutic and pharmacological 
interventions to delay or prevent onset of psychosis (Woodberry, Shapiro, Bryant, & 
Seidman, 2016). The diversity, complexity, and variedness of non-specific features of the 
prodrome coupled with the long-term impact of psychosis on cognitive, emotional, and 
social development have led to the development of several models to conceptualize the 
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high-risk state. These models provide criteria to assess symptoms to more accurately 
identify individuals at-risk and then to provide appropriate treatment.  
Basic Symptoms.  Early attempts to describe high risk symptoms were first made 
by Huber and Gross who identified basic symptoms as early manifestations of psychosis. 
These symptoms are essentially subtle subjective experiences of disturbance marked by 
changes in cognition, affect, and perception (Huber & Gross, 1989). This approach is 
based on retrospective studies on the prodrome and has gained widespread recognition in 
Germany and other parts of Europe as of the late 1990s. As explained by Larson, Walker, 
Compton (2010)  basic symptoms are the first symptoms to develop and are “subjective 
experiences of thought, language perception, motor disturbances; impaired bodily 
sensations; impaired tolerance to stress; disorders of emotion, thought, energy, 
concentration and memory; and, disturbances in social functioning.” (p. 4).  
Basic symptoms manifest as subjective experiences and are rarely outwardly 
observed by others. This approach proposes that there are levels of progression of 
symptoms with subtle non-specific cognitive disturbances emerging first, then thought 
interference, speech difficulties, automatic skills deficits appearing later, and then lastly 
frank psychosis (Schultze-Lutter et al., 2010). These symptoms can be further assessed 
using the subscales: cognitive-perceptive basic symptoms (COPER) and cognitive 
disturbances scale (COGDIS). COPER requires the presence of at least one of ten basic 
symptoms within the last three months and COGDIS requires the presence of at least two 
of nine basic symptoms within the last three months (Schultze-Lutter  & Theodoridou, 
2017).While this approach  is not widely recognized  in the United States, it has 
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influenced the development of other high-risk models which will be further expanded on 
below.  
Ultra High Risk. The basic symptom approach helped to lay the groundwork for 
high-risk research and also revealed some shortcomings in the current methodological 
approaches at the time. For instance, many subjects in research studies were incorrectly 
labeled as at risk for psychosis but did not actually develop psychosis (Falloon, 1992; 
Yung & Nelson, 2013). Previous studies also further highlighted the challenges of 
prospectively identifying individuals in the prodromal state due to nonspecific nature of 
prodromal symptoms. The ultra high risk (UHR) approach arose out of the need to 
minimize the concerns surrounding the false-positives and to widen the risk criteria to 
identify high-risk groups.  
The UHR approach considers the age of the individual acknowledging that 
psychotic symptoms tend to appear in adolescence or early adulthood, specificity of 
symptoms, and genetic and clinical risk factors in identifying those at risk. Additionally, 
the name ultra high risk, also distinguishes help-seeking individuals from other high-risk 
groups such as those who may have a genetic risk.  As explained by Yung & Nelson 
(2013), to meet UHR criteria, the individual must be between the ages of 15 and 25 years 
old, experience a decrease in functioning for at least one month or sustained low 
functioning during the past year, and meet criteria for one of the following groups: 
attenuated positive symptom syndrome (APS), brief limited intermittent psychotic 
syndrome (BLIPS), and trait vulnerability group. To meet criteria for APS, there must be 
the presence of attenuated psychotic symptoms within the past year. Individuals must 
endorse at least one of the following symptoms such as odd beliefs or magical thinking, 
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ideas of reference, perceptual disturbance, paranoid ideation, odd behavior or appearance, 
odd thinking and speech at the high-risk level. To meet criteria for BLIPS, individuals 
must endorse the same symptoms, but at a psychotic level of severity for a brief duration. 
These transient symptoms should last for less than one week and resolve spontaneously 
within a year. To meet criteria for trait vulnerability, an individual must present with a 
genetic vulnerability to a psychotic disorder such as having a family history of a 
psychotic disorder in a first-degree relative or the individual meeting diagnosis for 
schizotypal personality disorder.  
These ultra high risk categories were used to create the Structured Interview for 
Prodromal Syndromes (SIPS) along with its companion Scale of Prodromal Symptoms 
(SOPS) which were developed by McGlashan and colleagues at Yale University and are 
widely used in the United States.  According to McGlashan, Walsh and Woods (2010), 
the SIPS and SOPS were developed to identify the presence/absence of one or more of 
the psychosis risk-states; to measure the severity of risk symptoms cross-sectionally and 
longitudinally; and to define the presence/absence of psychosis. The SIPS also consists of 
the Criteria of Prodromal Syndromes (COPS) which provides operationalized definitions 
of the clinical high risk (CHR) syndromes: attenuated positive symptom syndrome 
(APS), brief intermittent psychotic syndrome (BIPS), and genetic risk and deterioration 
syndrome (GRD).  
 Clinical High Risk.   The Clinical High Risk (CHR) approach has incorporated 
ultra high risk criteria since its inception and also provides the basis for this current study. 
The Clinical High Risk approach developed by Cornblatt and colleagues at the 
Recognition and Prevention (RAP) Program proposes that high-risk symptoms progress 
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along a continuum and uses the SIPS and SOPS as the basis for this classification 
(Cornblatt et al., 2003).  
Compared to previous pioneers such as McGorry, Yung and colleagues, the RAP 
Program is unique as it incorporates a neurodevelopmental perspective to track the 
longitudinal progression of high-risk symptoms over time. As explained by Cornblatt 
(2002), the neurodevelopmental model of schizophrenia proposes that psychosis is the 
result of structural, functional, and biochemical abnormalities occurring during prenatal 
development. These abnormalities lead to a biological vulnerability which presents as 
cognitive deficits, affective symptoms, social isolation, and school failure. Subsequently, 
genetic, biological, or environmental triggers may then cause positive symptoms to 
develop which may lead to full-blown psychosis. Cornblatt et al (2015) explains that 
there are three stages: The first stage or pre-illness phase is marked by neurocognitive 
deficits, followed by the prodromal phase where behavioral changes are observed, and 
then the final stage of full-blown psychosis (See Figure 1).  
Early studies focused on the prodrome as a single entity, leaving very little room 
for the possibility of multiple pre-psychotic phases. The RAP program’s classification 
system shifted the way the prodromal phase is viewed by focusing on developmental 
stages. The RAP program’s classification system is grounded in the staging theoretical 
framework which has been widely used in medicine but only recently applied to studying 
the psychosis risk syndrome (McGorry et al., 2007).  Using the SIPS, the RAP Program 
developed criteria to classify individuals at high-risk based on the presence of positive 
and negative symptoms (Cornblatt et al., 2003).  According to Cornblatt and colleagues, 
there is an early period and late period in the prodromal phase of illness. In the early 
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prodromal phase, attenuated negative symptoms and affective symptoms begin to 
emerge, affecting an individual’s functioning.  The late prodromal phase is defined by the 
development of attenuated positive symptoms.  For some individuals, the symptoms then 
progress to psychosis.  
This developmental model proposed by Cornblatt and colleagues provides a 
number of different entry points into the prodrome and is categorized by stages. During 
the first stage referred to as Clinical High Risk Negative (CHR-), individuals may present 
with nonspecific, attenuated negative symptoms such as increased social isolation, school 
failure, decreased expression of emotions, and rigid thinking. For this stage, individuals 
must score at least a 3 on the SOPS on the negative symptom scale, signifying moderate 
to severe intensity.  This stage is then followed by the Clinical High Risk Positive (CHR 
+) stage where individuals present with attenuated positive symptoms with a SOPS score 
between 3 and 5. Symptoms reported may include disorganized speech, unusual thought 
content, cognitive changes, and perceptual abnormalities. The final category which is 
schizophrenia like psychosis (SLP), requires that an individual present with at least one 
psychotic level symptom (6 on the SOPS) but they do not meet full criteria for 
schizophrenia (Lencz, et al., 2004). For the purposes of this study, we will be focusing 
only on the CHR+ and the CHR- subgroups (See Figure 2).  
 This model allows one to track the progression of the illness over time, which also 
helps to inform stage-specific interventions. This also leaves space to further develop 
criteria to identify early risk factors for high-risk individuals. Research regarding 
appropriate interventions for high-risk individuals is crucial given the indeterminate 
nature of the high-risk state, the fact that the majority of high-risk individuals will never 
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develop psychosis, and the issue that many medications, namely antipsychotic 
medications, carry serious side effect risks (Corcoran, Malaspina, & Hercher, 2005). The 
choice of intervention in the prodrome is further complicated by the presence of frequent 
psychiatric comorbidities in high-risk individuals.   
Validity of High-Risk Syndromes  
 In studies detecting psychosis risk, high risk groups that are often referenced are 
ultra high risk (UHR) and clinical high risk (CHR). UHR is mostly used in Europe and 
Australia and is assessed by using the CAARMS, whereas, CHR is frequently used in 
North America and is assessed by the SIPS. Despite, some differences in the types of 
instruments used to assess risk, CHR and UHR are fairly similar in their categorization of 
high-risk individuals (Correll, Hauser, Auther, & Cornblatt, 2010; Miller et al., 2003). 
Both the SIPS/SOPS and CAARMS assess positive symptoms, negative symptoms, 
disorganization symptoms, and general symptoms (Correll, Hauser, Auther, & Cornblatt, 
2010).  
Several studies have been conducted to evaluate the diagnostic validity of the 
prodromal risk syndromes described above. The SIPS was first tested for validity in 
2000, with the results showing that 46% of the participants who met at-risk criteria 
developed schizophrenic psychosis after 6 months, and 54% at 12 months (Miller et al., 
2003). In a more recent study, the validity of the SIPS was assessed using a pooled 
sample from 8 academic research centers in North America: Emory University, Harvard 
University, University of California Los Angeles, University of North Carolina, 
University of California San Diego, University of Toronto, Yale University, and Zucker 
Hillside Hospital who are part of the North American Prodrome Longitudinal Study 
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(NAPLS) consortium. Results demonstrated that, of the 291 participants who completed 
follow-up, 82 converted to psychosis over 30 months.  The cumulative prevalence rate of 
conversion to psychosis was 35.3% over this time period (Cannon et al., 2008). In 
another NAPLS study evaluating predictive validity, prodromal risk participants were 
compared to several groups (e.g. normal controls, help-seeking controls, familial risk 
subjects, and subjects with schizotypal personality disorder) on different domains such as 
functioning, follow-up outcome, and symptom profile (Woods et al., 2009). Overall, the 
results showed that the prodromal risk participants were more symptomatic compared to 
the other groups and were more likely to convert to psychosis over a 2-year period. These 
findings support the diagnostic validity of this risk syndrome for psychosis (Woods et al., 
2009).  
 The use of valid and reliable assessment tools has been a critical step towards 
early identification and intervention strategies for high-risk individuals. The advancement 
in assessment tools have led the way to improving recruitment strategies, identifying 
symptoms, and increasing our understanding of the high-risk clinical presentation.  
Early Intervention Programs  
Early intervention research for psychotic disorders is viewed as having the 
potential to produce better outcomes in individuals vulnerable to developing psychosis 
and to reduce some of the clinical and economic burdens associated with the illness 
(Fusar-Poli et al., 2013; Stafford, Jackson, Mayo-Wilson, Morrison & Kendall, 2013). 
This line of logic is deeply rooted in preventative medicine research.    
Mrazek and Haggerty (1994) described some of the challenges in the 
classification system used to categorize prevention for physical illnesses. They pointed 
18 
 
out that the previous categorization primary, secondary, and tertiary prevention is 
ambiguous when applied to the prevention of progression of mental illness as it is unclear 
how prevention measures are implemented when there is no clinically diagnosable 
disorder. These researchers reorganized the classification system into universal 
prevention, selective prevention, and indicated prevention. Indicated prevention, which 
targets high risk individuals who present with minimal but detectable symptoms is of 
particular importance in early intervention research as it targets individuals who are of 
especially high risk of developing serious mental disorders such as psychosis (Mrazek & 
Haggerty, 1994, p.22-24).  
 Within the last 30 years there has been emerging interest in indicated prevention 
which has paved the way for high-risk research and treatment by helping researchers and 
clinicians explore methods to prevent or postpone the onset of psychosis and develop 
treatment options to address presenting symptoms. Ideally, indicated prevention may 
provide potential benefits where help-seeking individuals either return to their previous 
level of functioning or maintain their current level of functioning (Correll, Hauser, 
Auther, & Cornblatt, 2010; Fusar-Poli et al., 2016). The field of prevention research is 
exciting as it sheds light on the development and course of psychotic illness. It also 
involves identifying individuals who are in the pre-psychotic phase of illness, meaning 
that they are presenting with prodromal or high-risk symptoms.  
    Early intervention programs consist of a multidisciplinary team of mental health 
professionals who provide therapeutic and psychopharmacological interventions that are 
tailored to the needs of help-seeking individuals (McGorry, Killackey, & Yung, 2007).  
High-risk research and treatment programs have proliferated around the world and been 
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largely successful and informative in increasing our understanding of high-risk states. 
Australia and some parts of Germany were the front runners for early intervention 
programs, but now there are many programs that can be found in the United States, 
Canada, and Asia. These programs vary in their methodological approaches, assessments, 
and duration while offering support to help-seeking individuals and their 
families/caregivers (McGorry, Killackey, & Yung, 2008). 
Effective treatments have been identified through these early intervention 
treatment programs. For instance, cognitive therapy, which has been shown to be 
effective in mitigating effects of psychosis may also reduce the severity of psychotic 
symptoms in young individuals when utilized as a preventative intervention (Morrison et 
al., 2012).  Comparatively, in another study conducted by McFarlane et al (2015), a 
therapeutic intervention called Family-aided Assertive Community Treatment (FACT) 
was proven to be effective in improving negative, disorganized, and general symptoms. 
Other studies have investigated potential beneficial effects of omega-3 fatty acids on 
preventing onset of psychosis (Amminger, et al.,  2015; Mosshaeb, 2012). Additionally, a 
meta-analysis assessing the efficacy of early intervention treatment options revealed that 
omega-3 and CBT demonstrated good effect in reducing transition rates in high- risk 
participants.  Antipsychotic medications were mostly found to be somewhat effective in 
delaying conversion to psychosis, but are associated with side effects and high attrition 
rates.  (van der Gaag et al., 2013).  
 It is also noteworthy that in North America, many sites have collaborated to form 
the aforementioned NAPLS which is a consortium of eight early intervention programs in 
North America.  Sites participating in the NAPLS consortium contributed their 
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preexisting data sets to form a larger sample of CHR individuals with more power to 
further assess outcomes. These early intervention programs have largely contributed to 
high-risk research by exploring treatment options, neuropsychological profiles, and risk 
algorithms for CHR individuals. Treatment outcomes from recent NAPLS studies have 
revealed that CHR participants are more likely to report experiencing stressful life events 
and to experience daily hassles (Trotman et al., 2014) and also report higher baseline 
cortisol levels compared to healthy controls (Walker et al., 2013). Based on several 
NAPLS studies, there are observed impairments in functioning for CHR individuals 
(Fusar-Poli et al., 2013; Piskulic et al., 2016; Seidman et al., 2010; Seidman et al., 2016; 
Velthorst, 2019). Cornblatt et al. (2012) found that social and role functioning remained 
relatively stable in CHR subjects who converted to psychosis. In contrast, role 
functioning improved over time in nonconverters. Additionally, using multivariate 
models, NAPLS studies have identified biomarkers (e.g., neuroimaging and 
electrophysiology) and predictive algorithms to more accurately identify predictors for 
conversion (Cannon et al., 2016).  This consortium went on to collect prospective genetic 
samples and conducted further research on the biological underpinnings of psychosis.  
The Recognition and Prevention (RAP) Program. A program founded by 
Barbara Cornblatt in 1998 and is one of the first early intervention programs in North 
America to investigate and treat individuals who are high risk for psychosis. Since its 
inception, the program has contributed to research on the progression of symptoms in 
CHR individuals while offering educational resources and treatment options for young 
adults and their families. 
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Research studies of the RAP Program have focused on identifying vulnerability 
markers that may be unique to CHR individuals. Studies from the RAP Program have 
specifically concentrated on social functioning, role functioning, and overall 
neurocognitive functioning using a variety of testing batteries and assessments. RAP 
studies consistently demonstrate that CHR individuals report significant impairments in 
social and role functioning suggesting that these impairments may serve as potential risk 
factors (Carrión et al., 2011, 2013; Cornblatt et al., 2012; Olvet, Carrión, Auther, & 
Cornblatt, 2015). In a study conducted by Carrión et al. (2018) comparing baseline 
neurocognitive performance across different groups (healthy controls, CHR individuals, 
and individuals in the early first- episode phase of psychosis), it was found that verbal 
learning impairment was most predictive of conversion to psychosis. This finding is 
noteworthy, implying that verbal learning may be a vulnerability marker and could 
inform specific interventions for high-risk individuals. Additionally, CHR individuals 
who did convert to psychosis presented with similar functioning compared to those 
subjects in the early first-episode phase of psychosis, supporting the likelihood of 
functioning declining during the progression of psychosis (rather than as a result of 
psychosis). In another study comparing CHR subjects to healthy controls, CHR subjects 
highlighted that auditory mismatch negativity (MMN)  may impact baseline functioning 
and is negatively correlated with reading ability, social and role functioning (Carrión et 
al., 2015). Other studies have found that longer duration of negative symptoms to be 
associated with poorer social functioning, severity of attenuated positive symptoms to be 
a predictor of conversion to psychosis, and disorganized symptoms, impaired social 
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functioning, and low processing speeds to predict poor social functioning (Carrión et al., 
2016; Carrión et al.,2013).  
Using the framework of the RAP model, this study aims to further explore the 
progression of symptoms in CHR subjects and how clinical profiles may evolve during 
different stages of the model.  
Psychiatric Comorbidities in High-Risk Populations  
As mentioned previously, the psychiatric comorbidities with schizophrenia have 
been well-documented. Given the cooccurrence of nonpsychotic disorders with high- risk 
symptoms, it is important to examine the prevalence rates, progression of these disorders, 
and functional outcomes in high-risk youth. It is essential to accurately identify comorbid 
disorders as this has implications for early intervention and treatment options. This study 
will assess the course of Axis I and Axis II disorders using DSM-IV criteria, which was 
in use at the time of data collection. 
Prevalence of Axis I Disorders  
Mood and Anxiety Disorders. Similar to findings in schizophrenia research, 
affective and anxiety disorders are frequently observed in the high-risk population and 
may prompt help-seeking individuals to seek treatment. 
 An earlier retrospective study of the schizophrenia prodrome conducted by 
Hafner and colleagues (1998), identified depression as the most frequently endorsed 
symptom preceding the onset of psychosis. Hafner and colleagues suggested that 
depression might actually be an expression of the development of psychotic illness 
process. Later studies assessing the progression of depressive symptoms confirmed that 
depression may impact psychosis onset (Yung et al., 2007).  
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A recent meta-analysis of prospective high-risk studies found that about 73% of 
at-risk participants had at least one comorbid Axis I diagnosis, with the most common 
being depressive and anxiety disorders (Fusar-Poli et al., 2014).  Research findings show 
that non-bipolar mood disorders appear to be prevalent in the high-risk population. Fusar-
Poli et al. (2014) found that 41% of high-risk subjects met criteria for a depressive 
disorder. In a NAPLS study consisting of 377 participants, 55% met criteria for a 
depressive disorder (Woods et al., 2009). In another study assessing transition to 
psychosis in a CHR sample, it was observed that 34% of participants met criteria for a 
depressive disorder (Salokangas, et al., 2012). Among several high-risk studies, major 
depressive disorder appears to be the predominant mood diagnosis in this population 
(Kline et al., 2018; Lin et al., 2015; Meyer et al., 2005; Rosen et al., 2005; Salokangas, et 
al., 2012). Depressed mood appears to be associated with poor role and social functioning 
(Fulford et al., 2013). In another study assessing the prevalence of depressive disorders, 
CHR participants with current or past depression also demonstrated more impairments in 
functioning and more severe negative symptoms (Kline et al., 2018).  
Anxiety is also commonly observed in the CHR population (Addington et al., 
2011; Fusar-Poli et al., 2014; Woods et al., 2009). In one study consisting of a CHR 
sample of 765 subjects, 51% met criteria for an anxiety disorder with social phobia being 
the most common. (McAusland et al., 2017). Other studies have replicated similar 
findings of social phobia being the most prevalent of all anxiety disorders among high-
risk individuals (Hui et al., 2013; Meyer et al., 2005; Svirskis et al., 2005).  
Several longitudinal studies have been conducted to assess obsessive compulsive 
disorder (OCD) in high-risk individuals.  One study revealed sizable prevalence rates of 
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20% in high-risk youth, but after 12 months none of the individuals diagnosed with OCD 
converted to psychosis (Niendam et al., 2009).  In contrast, in another study with a 12-
month follow-up, OCD symptoms at baseline predicted incident diagnosis of a psychotic 
disorder at 12-month follow-up, showing that when attenuated psychotic symptoms are 
accompanied by OCD symptoms, the risk for transition to psychosis increases (Van Dael 
et al., 2011). Another study found that a diagnosis of incident OCD was associated with 
higher rates of psychotic disorders at 7-year follow-up (Fontenelle, 2011). Fontenelle and 
colleagues (2012) completed another study a year later where they assessed markers for 
vulnerability to OCD with results demonstrating that participants who presented with 
OCD and psychosis after the 7-year follow-up period displayed more severe levels of 
depression and anxiety after conversion to psychosis.  
 Studies exploring the occurrence of comorbid Axis I disorders at baseline in at 
risk participants found that common baseline diagnoses are major depressive disorder 
(50%), anxiety disorders such as anxiety disorder not otherwise specified (NOS; 17%), 
obsessive compulsive disorder (6.4%), and social phobia (17%; Fontenelle et al., 2011; 
Meyer et al., 2005).  In another study assessing the prevalence of depressive and anxiety 
disorders in at-risk mental state (ARMS) participants, 40% of participants had a 
comorbid depressive disorder, 8% had an anxiety disorder and 14% of participants had 
both a depressive disorder and anxiety disorder (Fusar-Poli et al., 2014). These studies 
confirm the common occurrence of anxiety and depressive disorders in high-risk 
populations.   
 Attention Deficit and Disruptive Behavior Disorders.  The well-documented 
research on the overlap of symptoms associated with ADHD, disruptive behavioral 
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disorders, and psychosis has also led to further research on how these symptoms manifest 
before the onset of full-blown psychosis. Many individuals who are high-risk for 
developing psychosis also present with ADHD diagnoses, externalizing behaviors, and 
academic concerns (Karatekin, White, & Bingham, 2010). As explained by Simeonova, 
Nguyen, and Walker (2014) “The general pattern of findings suggest that pre-psychotic 
youth are more socially isolated, withdrawn, emotionally labile, anxious, and aggressive 
than their healthy siblings and/or age-matched comparison subjects. They also have 
higher levels of impaired attention, which remain stable and elevated from childhood to 
adolescence, and are assumed to negatively affect social interactions leading to increased 
stress related to social situations” (p.2). Some studies even suggest that ADHD may be a 
vulnerability marker for psychosis but findings are inconsistent (Diwadkar, et al., 2011; 
Keshavan et al., 2003).  
 There is evidence that inattention difficulties manifest for help-seeking 
individuals who are high-risk (Francey et al., 2005; Pukrop et al., 2007; Simon et al., 
2007). Hurtig et al (2011)  linked psychotic-like experiences to inattentive symptoms 
(Hurtig et al., 2011). An earlier study conducted by Mazzoni et al (2009) demonstrated 
that childhood-onset disorders were prevalent in young adults who met criteria for being 
in the pre-psychotic phase. In this relatively small sample of 9 participants, diagnoses that 
were endorsed included ADHD, elimination disorders, oppositional defiant disorder, 
enuresis or encopresis, conduct disorder, separation anxiety, and transient tic disorder. 
These findings support the viewpoint of a developmental perspective when exploring the 
progression of symptoms in the high-risk state.  
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 Recent studies have further explored the connection between disruptive 
behavioral disorders and identifying at risk youth. A more recent study conducted by 
Simeonova et al.(2014), investigated whether or not parents’ report of social and 
behavioral problems on the CBCL (Child Behavior Checklist) can be used to identify at 
risk youth. Results indicated that the CBCL scales: Withdrawn/Depressed and Thought 
Problems were the most useful in identifying at-risk youth which has implication for 
developing future screening measures.  
  Substance Use.  Research on the patterns and rates of substance usage in high-
risk individuals varies which has led to interest in clarifying the relationship between 
substance use and transition to psychosis. There are also differences in reports of rates of 
substance abuse and dependence cooccurring within the pre-psychotic phase but the 
consensus appears to be that cannabis, nicotine, and alcohol are the most commonly 
reported used substances in CHR  populations (Addington et al., 2014).   
 Varying rates of cannabis use and cannabis use disorders has been observed in 
high-risk samples. Phillips et al., (2002) found that 37% of subjects reported using 
cannabis at least once and 18% of subjects met criteria for cannabis dependence. Corocan 
et al. (2008) observed that 41% of high-risk individuals endorsed cannabis use. Several 
studies also compare cannabis use to use of other substances, citing varying rates among 
high-risk participants. In a study conducted by Auther et al. (2015) baseline comparisons 
revealed that alcohol use was reported in 45.3% of CHR youth and cannabis use rates 
were 38.1%. Additionally, 85% of participants who reported cannabis use also reported 
alcohol use, implying that individuals in this population are likely to use multiple 
substances. In another study, at-risk participants reported increased tobacco, alcohol 
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and cannabis use compared to controls and a noteworthy finding was that at-risk status 
was significantly associated with higher alcohol use (Carney et al., 2017).  Findings from 
Buchy et al. (2014) cited that CHR participants endorsed more significant cannabis and 
tobacco use and lower alcohol use over a one-year period. Also, in comparison to healthy 
controls, CHR youth were more likely to report higher prevalence rates and frequencies 
of cannabis use, the age of onset of use was younger, and they were more likely to use 
cannabis alone. However, Russo et al. (2014) observed that healthy controls reported 
higher cannabis use but lower alcohol use compared to high-risk individuals. It also 
appears that use of more elicit substances is uncommon among CHR youth (Addington et 
al., 2014; Buchy et al, 2015).  
Prevalence of Axis II disorders 
 Research concerning personality pathology in at-risk participants is scarce but 
there is evidence suggesting that schizotypal personality disorder (SPD) traits are similar 
to the characteristic symptoms of schizophrenia, but are less severe (Ericson, Tuvblad, 
Raine, Young-Wolff & Baker, 2011). The criteria for SPD can be separated into three 
symptom dimensions (positive, negative, and disorganized) which are also consistent 
with the diagnostic criteria for schizophrenia. Since, the criteria for SPD may be 
attributed to a genetic loading or vulnerability to developing schizophrenia, it is actually 
ideal for use in identifying individuals at-risk for psychosis. In fact, several strategies 
have been used based on these criteria. Individuals are considered to meet at-risk 
syndromes if they experience a recent onset of attenuated psychotic symptoms including 
at least one of the following SPD symptoms: ideas of reference, odd beliefs, magical 
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thinking, perceptual disturbance, odd thinking and speech, paranoid ideation, and odd 
behavior or appearance.  
 High-risk symptoms and SPD shares some similar features but SPD is an 
independent syndrome. The major distinguishing feature is that SPD is thought to be 
longstanding and stable while high risk symptoms are thought to be progressing. 
However, there are major gaps in the literature regarding the stability of this disorder. 
There is a study conducted by Ericson and colleagues in 2011 which investigated the 
genetic and environmental etiology of SPD traits in adolescent twins.  These individuals 
were identified as presenting with SPD traits and were assessed on two occasions 
between the ages of 11 and 16 years old. They found genetic variance in the SPD traits 
with moderate stability in SPD traits between early to middle adolescence. The 
researchers suggested that future studies of schizotypal traits in individuals with 
prodromal symptoms need to further explore other factors that may be operating (Ericson 
et al., 2011) 
While the research does suggest that the most common Axis II diagnosis is 
schizotypal disorder for high-risk individuals with a prevalence rate of 21%, there is 
some evidence that other personality disorders are present for this group as well. In a 
study reporting on high-risk participants who did not convert to psychosis, Addington et 
al. (2011) looked at Axis I and Axis II diagnoses and found that 29% of the sample had 
consistent diagnoses at baseline and follow-up of avoidant, borderline, schizotypal, and 
paranoid personality disorders and 14% had emerging diagnoses of avoidant, borderline, 
and obsessive compulsive personality disorders at follow-up. These findings also 
encourage further exploration of personality disorder development over time.  
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 Borderline personality disorder (BPD) has also observed in high-risk individuals. 
Some of the symptoms associated with BPD are similar to attenuated positive symptoms 
which are essential in establishing high-risk criteria. There is evidence to suggest that 
individuals with BPD are likely to experience hallucinations, body image distortions, and 
ideas of reference, especially during stressful periods (Thompson et al., 2012). The 
prevalence rates for BPD in high-risk individuals are inconsistent with reports as low as 
5% or as high as 17% (Lencz et al., 2004; Rosen et al., 2006).  More recently Ryan et al. 
(2017) reported prevalence rates of 25%. Although Rosen and colleagues found 
prevalence rates of 17% for BPD, there was no difference in prevalence rates of their 
high-risk sample compared to their control sample.  Based on these findings, it remains 
unclear if there is a true difference in presentation of this disorder and how it contributes 
to our understanding of personality disorder pathways that may be linked to the 
development of psychosis.  
Thompson and colleagues attempted to further explore these issues, finding that 
there was no difference in the rates of transition to psychosis in individuals with baseline 
BPD compared to those without the diagnoses. In addition, reports of BPD symptoms at 
baseline were not related to the onset of a particular psychotic disorder.  
 With limited research, it still remains unclear as to whether or not there is a 
distinction between individuals whose high-risk symptoms are manifested in their 
personality framework and individuals who are truly at risk for psychotic disorders. This 





Attenuated Positive and Negative Symptoms 
Individuals who are high-risk for psychosis may experience attenuated positive 
and negative symptoms in addition to psychological difficulties which may induce further 
distress. While there is considerable research on how positive and negative symptoms 
present and develop in this population, less is known about the relationship between 
attenuated symptoms and co-occurring psychiatric disorders (Carrion et al., 2016; Davies 
et al., 2018, Lencz et al., 2004).  
Anxiety and mood disorders have been found to be strongly associated with 
attenuated positive symptoms and negative symptoms (Addington et al., 2011). Some 
studies suggest that high-risk individuals who meet criteria for anxiety disorder or 
depression are more likely to endorse worsening negative symptoms (Falkenber et al., 
2015; McAusland et al., 2015). Individuals who meet criteria for anxiety disorders, 
depressive disorders, or both are more likely to endorse attenuated positive symptoms 
such as suspiciousness (McAusland et al., 2017). There is also evidence to support that 
anxiety disorders are related to certain attenuated positive and negative symptoms such as 
hallucinations and withdrawal, and blunted affect (Lysaker & Salyers, 2007). 
Few studies have explored the relationship between substance use and attenuated 
symptoms. One longitudinal study examining the relationship between substance use and 
clinical measures found a link between cannabis use and hallucinations/perceptual 
disturbances which are positive symptoms. In this study it was also observed that positive 
symptoms worsened with increase in cannabis use and improved or remitted when high-
risk individuals stopped cannabis use altogether (Corcoran et al., 2008). Similarly, 
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findings from Wade et al (2007) determined that heavy substance use was associated with 
attenuated positive symptoms.   
Cluster A personality disorders (schizoid, schizotypal, paranoid personality 
disorders) share symptoms that may overlap with attenuated positive and negative 
symptoms. In particular, schizotypal personality disorder is used as a marker to identify 
individuals who are high-risk for psychosis and is characterized by positive symptoms 
such as suspiciousness, odd thinking, perceptual disturbances and negative symptoms 
such as inappropriate affect, diminished emotional expression, social anhedonia, and 
avolition (Esterberg et al., 2010).  Zoghbi and colleagues confirmed this in a study 
consisting of a sample where SPD was highly prevalent and found to be associated with 
attenuated positive and negative symptoms (Zoghbi et al, 2019). A defining feature of 
paranoid personality disorder is suspiciousness, which is a positive symptom and schizoid 
personality disorder consists of negative symptoms such as avolition, flat affect, and 
social anhedonia (American Psychiatric Association, 2000).  As these personality 
disorder traits present with similar features of positive and negative symptoms, it is 
expected that Cluster A personality disorders will be associated with attenuated positive 
and negative symptoms.  
Studies exploring the relationship between attention-deficit and disruptive 
behavior disorders and attenuated symptoms in high-risk populations are scarce. There is 
evidence to suggest that high-risk individuals with these disorders are emotionally labile, 
present with disorganized communication, and are inattentive which are similar features 
of positive and negative symptoms (Miller et al., 2002).  One study investigating social 
and behavioral problems on the CBCL found that the Withdrawn/Depressed scale closely 
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resembled negative symptoms and the Thought Problems scale resembled positive 
symptoms and are useful instruments for identifying at-risk youth (Simeonova et al., 
2014).  
In this study we hope to further explore the relationships between psychiatric 
disorders and attenuated positive and negative symptoms. We expect that psychiatric 
disorders will be associated with higher levels of attenuated positive and negative 
symptoms. We also hope our findings will help to further clarify these relationships. 
Social and Role Functioning  
 For many high-risk individuals, social and role functioning difficulties manifest 
before first-episode psychosis and the impact may be more noticeable than the actual 
attenuated positive and negative symptoms (Addington & Addington, 2005). The 
development of high-risk symptoms may cause individuals to isolate themselves from 
peers, feel “othered”, and disconnected from themselves. These symptoms may also 
impact academic achievement, success, and completing tasks for work and school. 
Although social and role functioning is widely studied in high-risk individuals, less is 
known about the relationship between functioning and psychiatric disorders in this 
population. Based on the pre-existing literature, we do expect there to be lower levels of 
social and role functioning associated with mood disorders, anxiety disorders, attention-
deficit and disruptive behavior disorders, and personality disorders.  
Earlier studies on the prodrome have cited impairments in social and role 
functioning in conjunction with mood and anxiety disorders to be defining characteristics 
of the prodrome (Yung and McGorry, 1996). Comorbid anxiety and depressive disorders 
coupled with the at- risk symptoms have an adverse impact on baseline functioning levels 
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in the participants. For anxiety disorders, social anxiety in particular is associated with 
lower levels of social functioning. (Chudleigh et al. 2011). One study clarifying this 
relationship suggests that dysphoric mood is associated with lower levels of role and 
social functioning (Fulford et al, 2013). It has also been found among CHR participants 
that participants with current and past depressive histories present with more significant 
impairments in social functioning compared to those participants who did not have a 
history of depression (Kline et al., 2018). The experience of anxiety and mood disorders 
could further exacerbate social functioning deficits, leaving individuals feeling 
dissatisfied with their social connections. Additionally, less severe mood and anxiety 
disorders are associated with improvement in both social and role functioning, suggesting 
that anxiety and mood disorders may indeed be contributors to social and role function 
deficits in high-risk groups (Schlosser et al., 2012).  
 Attention-deficit and disruptive behavior disorders are also associated with lower 
levels of social and role functioning in adolescents, evidenced by deficits in executive 
functioning and emotional processing. Individuals in the prepsychotic phase may  display 
low frustration tolerance, impulsive behavior, have difficulties with focus and attention 
making it difficult to perform well in school and maintain close connections with peers 
(Cadesky,  Mota, & Schachar, 2000; Marsh & Williams, 2006).  
 In examining the relationship between substance use and functioning, Auther and 
colleagues compared substance use in CHR participants to healthy controls. Lifetime 
CHR cannabis users reported higher social functioning, CHR cannabis users had higher 
social functioning compared to nonusers at follow-up and reported no significant 
differences in role functioning (Auther et al., 2012). In another study, adolescents who 
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had an earlier onset of cannabis use disorder (before age 15) demonstrated better social 
functioning and were more likely to perform poorly academically (Compton et al., 2011). 
Similarly, in another study, early onset of cannabis use was associated with higher levels 
of social functioning compared to nonusers (Bagot, Milin, & Kaminer, 2015). Based on 
these findings, it appears that cannabis use is related to better social functioning.  
 Personality disorders impact the ability to get along with others and perform well 
academically and in work environments. The role of social and role functioning is 
included under the general diagnostic criteria in the DSM-IV-TR (American Psychiatric 
Association, 2000) specifying that this “enduring pattern leads to clinically significant 
distress or impairment in social, occupational, or other important areas of functioning ” 
(p.689). However, this is not specifically included as diagnostic criterion for each of the 
personality disorders. Oltmanns and colleagues explored the relationship between social 
functioning and personality disorders. In a sample of 577 participants, 33% met criteria 
for a personality disorder. Results indicated that impairment in social functioning is 
associated with personality pathology. More specifically, participants who endorsed a 
Cluster A personality disorder (paranoid, schizoid, and schizotypal) also reported lower 
social functioning (Oltmanns et al., 2002).  
Predictors of Conversion  
 Although the majority of individuals in a high-risk sample do not transition to 
psychosis it is still imperative to identify these predictors to inform early intervention 
treatment and also provide important information about converters and non-converters.  
Several studies highlight that positive symptoms are the most robust and reliable 
predictors of conversion (Cannon et al., 2008; Gee & Cannon, 2011; Ruhrmann et al., 
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2008;  Yung et al., 2003). A study analyzing baseline demographics and clinical 
predictors of psychosis in a CHR sample, reported that higher SIPS scores on positive 
symptoms were predictive of conversion, suggesting that the severity of positive 
symptoms may be associated with more severe psychosis. (Zhang et al., 2017).  
There is evidence to support that anxiety disorders are not predictors of 
conversion. In a large-scale study of 509 at-risk subjects, exploring comorbid diagnoses 
and their impact on transition outcomes, it was found that anxiety disorders did not have 
an impact on transition to psychosis (Fusar-Poli et al., 2014). In another study conducted 
by McAusland et al (2014), 51% of CHR participants met criteria for an anxiety disorder 
but anxiety disorders did not predict transition to psychosis.  
Mood disorders have been proven to be predictors of conversion. In an EPOS 
study, bipolar and depressive disorders were shown to predict conversion to psychosis 
over anxiety disorders (Salokangas et al., 2012).  
Specifically, with cannabis use, the research findings on the association between 
use and transition to psychosis have been inconsistent. Phillips and colleagues did not 
find that cannabis use or dependence impacted transition to psychosis (Phillips et al., 
2002). Similarly, another study, conducted by Buchy and colleagues with a sample of 170 
CHR subjects found that cannabis use did not predict later conversion to psychosis 
(Buchy et al., 2014). Additionally, low to moderate lifetime cannabis was found not to 
predict transition to psychosis in another sample (Auther et al., 2012). Yung et al., 2004 
also did not find an association between conversion to psychosis and cannabis abuse. 




 Other studies have found a link between cannabis use and transition to psychosis. 
One study found that age of onset of cannabis use was associated with onset of high-risk 
symptoms suggesting that cannabis use may play a role in the development of psychosis 
(Dragt et al., 2012). Similarly, another study found that early onset of cannabis use 
(before age 15), frequency of use, and continued use were associated with transition to 
psychosis (Valmaggia et al., 2014). 
 Regarding other substances, there are mixed findings on the association between 
nicotine use and conversion. Kristensen & Cadenshead (2007) observed a line between 
nicotine use and conversion. In this same study, among the 6 participants who converted 
to psychosis, 4 of them smoked cigarettes. Similarly, Weiser et al. (2004) observed that 
the risk for schizophrenia was higher in adolescents who smoked at least one cigarette a 
day. Additionally, there was a significant association between the number of cigarettes 
smoked and the risk for psychosis as higher nicotine use was associated with higher- risk 
for psychosis. However, Zammit et al. (2003) found low rates of transition to psychosis 
among cigarette smokers  
Course of Axis I and Axis II Disorders 
Although the above studies have been instrumental in providing information 
about the occurrence of Axis I disorders in high-risk individuals, less is known about how 
these disorders impact long-term outcomes.  Some studies that have attempted to address 
this issue through longitudinal studies. McAusland and colleagues (2017) found that 51% 
of their sample met criteria at the 24-month follow up for anxiety disorder with several 
participants presenting with more than one anxiety disorder. 
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 Lin et al. (2015) investigated the comorbidity rates of nonpsychotic diagnoses in 
high-risk individuals at the 12-month follow-up and found high prevalence rates of 
depressive and anxiety disorders at follow-up of 48.7% and 34.5% respectively. 
Participants meeting criteria for more than one disorder at follow-up presented with more 
severe symptoms, higher distress, and lower functioning. In their study, 68.1 % of their 
at- risk participants met diagnostic criteria for at least one Axis I disorder at the 7-year 
follow-up period with mood disorders (48.7%), anxiety disorders (34.5%), and substance 
use disorders (29.2%) being the most common. In this sample, comorbid mental disorders 
had the tendency to persist or recur (51.6% persistent/recurring vs. 26.0% remittent 
course). Specifically, mood disorders (38.4%) and then followed by anxiety disorders 
(16.2%) were the most persistent /recurrent disorders. Incident diagnoses developed in 
37.5% of participants and 7.3% had no diagnoses. Comorbid disorders were associated 
with lower GAF scores at one-year follow-up. These findings suggest that Axis I 
disorders tend to persist over time and are correlated with functioning deficiencies. This 
dissertation study will follow the methodological approach described by Lin et al. (2015) 
to explore the developmental course of psychiatric disorders in the RAP sample.  
We expect to have similar findings with anxiety and mood disorders being the 
most persistent and recurrent in this study. We will further expand on Lin et al and 
colleagues’ study by also assessing the progression of psychiatric disorders using the 
clinical staging RAP model and comparing progression of disorders in the RAP 
subgroups.  Additionally, we added attention-deficit  and disruptive behavior disorders 
and personality disorders to our analyses to explore the progression of these disorders.   
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Aims and Hypotheses 
Aim 1:  Examine the baseline prevalence rates of psychiatric disorders in the 
sample of CHR participants (CHR + and CHR- groups) in the RAP Program. This 
study will  determine if there are differential rates of psychiatric disorders 
between the RAP prodromal groups (CHR-, CHR+) compared to each other. This 
study will also assess the relationship between psychiatric disorders and 
attenuated symptoms and functioning. 
Aim 2: Examine the long-term stability of psychiatric disorders in CHR 
participants in the RAP Program. Determine if there are differential rates of 
stability (persistent/recurrent, remitted, incident, and never present) of psychiatric 
disorders for the RAP high-risk groups (CHR-, CHR+). 
Aim 3: Identify whether positive symptoms predict conversion over and above 
Axis I disorders.   
Hypotheses for Aim 1 
Hypothesis 1: There will be no differences in rates of comorbid psychiatric 
disorders between the RAP prodromal groups (CHR- and CHR+).  
Hypothesis 2: Comorbid psychiatric disorders will be related to higher attenuated 
positive and negative symptoms, poorer social/role functioning scores at baseline.  
 
Hypothesis for Aim 2 
Hypothesis 3: In comparison to other psychiatric disorders, mood and anxiety 
disorders will be persistent/recurrent from baseline to last follow-up for both 




Hypothesis for Aim 3 
Hypothesis 4:  Attenuated positive symptoms will be a significant predictor of 
conversion to psychosis over and above Axis I disorders at baseline. Additionally, 
of all the Axis I disorders, mood disorders at baseline will be the strongest 




















Chapter 3: Methods 
Ethics in Research  
This study used previously collected data by the Recognition and Prevention 
(RAP) Program and was therefore determined to be exempt by St. John’s University’s 
Institutional Review Board (IRB: #1118 143), which reviews all research for compliance 
with ethical guidelines. Researcher was also granted permission to use data for 
dissertation by P.I. Dr. Barbara A. Cornblatt, Ph.D., M.B.A.  
Participants 
 Participants were 156 (110 males and 46 females) who participated in the 
Recognition & Prevention (RAP) Program during Phase I (2000-2006). The RAP 
Program has been continuously funded by the National Institute of Mental Health 
(NIMH) since 2000. It is located at The Zucker Hillside Hospital (ZHH) which is part of 
the Northwell Health hospital system in New York. The RAP Program conducts research 
and provides interventions for adolescents and young adults who present in the prodromal 
or high-risk stage of psychotic illness.  
All participants were help-seeking individuals referred from health care providers 
in the inpatient and outpatient psychiatry departments at ZHH, from private practitioners 
in the community, or were self-referred. Participants between the ages of 12-22 years of 
age were recruited for this study if they met criteria for one of the CHR categories: 
Clinical High Risk Negative (CHR-) and Clinical High Risk Positive (CHR+). High risk 
participants were included in the RAP Program research based on the presence of 
attenuated positive and negative symptoms as assessed by the SOPS measure. 
Participants with at least one attenuated negative symptom at a moderate (score of 3) or 
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higher level, but with no attenuated positive symptoms, were classified as Clinical High 
Risk – Negative (CHR -). Participants with at least one attenuated positive symptom in 
the moderate (score of 3) to severe (score of 5) range were classified as Clinical High 
Risk – Positive (CHR+). The final category of the RAP model  is the Schizophrenia-like 
Psychosis (SLP) group, defined as a person who has a positive symptom that has reached 
a psychotic level (score of 6). This is thought to be an intermediate stage between the 
prodrome (CHR- and CHR+ groups) and a full diagnosis of schizophrenia. Please see 
Figure 2. Note that in this dissertation, the SLP group will not be used.  
Participants were excluded from the study if they met criteria at baseline for a 
diagnosis of a schizophrenia-spectrum disorder (i.e. schizophrenia, schizophreniform 
disorder, schizoaffective disorder, delusional disorder), a mood disorder with psychotic 
features, or a bipolar spectrum disorder. Participants were also excluded if they had lack 
of English fluency, an estimated IQ <70, or a diagnosis of a medical or neurological 
disorder known to affect the developing brain.  
Procedures 
 Participants who met criteria for the study were informed of the research 
protocol, given the opportunity to ask questions, and were invited to participate in the 
study.  Written informed consent was obtained from participants 18 years of age and 
older or from a parent or guardian if participant was under the age of 18 (in addition to 
written assent).  Participants were informed that their participation in the study was 
voluntary and that they could withdraw from the study at any time.  
For this study, confidentiality was maintained by the assignment of subject 
numbers to participants in the study.  Data collected from participants were kept in 
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locked file cabinets at Zucker Hillside Hospital. Risks associated with participation in 
this study include possible fatigue or discomfort when responding to questions especially 
over a lengthy period of time.  Benefits of participation in this research include 
identification of disorders that may be impacting the individual’s functioning. This 
information could also be used to help the individual secure a referral for treatment. 
Other benefits include advancing our knowledge and understanding of individuals who 
are at-risk for psychosis with the hope of identifying effective forms of treatment. All 
procedures were approved by the IRB at Northwell Health. 
Testing procedures consisted of a battery of clinical, behavioral, functional, and 
neurocognitive measures taking approximately 3.5 hours that were collected at baseline 
and approximately every 6 months for up to 5 years. Average length of follow-up is 2.9 
years and therefore had varying follow-up times. Participants were compensated $10 an 
hour for their time and effort while participating in the research procedures. For the 
purposes of this dissertation, only data concerning prodromal symptoms, Axis I and Axis 
II disorders, and social and role functioning obtained via structured clinical interviews 
will be analyzed.  
Generally, parents/guardians were interviewed before the participant as they could 
provide useful information that could be used when interviewing participants.  After 
interviewing the parent/guardian, the assessor interviewed the participants, noting and 
reconciling any discrepancies in the reports. Assessors were all at the master’s level or 
above and were trained in administration and scoring of all the measures. Once 
completed, interviews were then scored by the interviewer and presented to an expert 




Demographic Variables. Age, sex, and US census-based race and ethnicity 
categories were obtained for each participant. Subjects and their guardians provided 
demographic information regarding age, sex, racial/ethnic identification, education, and 
annual household income. The instruments show good face validity and are typical of 
those used for research in hospital settings. Estimated IQ was obtained by administering 
the Vocabulary and Block Design subtests from the Wechsler Intelligence Scale for 
Children-Third Edition (WISC-III; Wechsler, 1991) and the Wechsler Adult Intelligence 
Scale-Revised (WAIS-R; Wechsler, 1981) depending on the age of the participant.  
Assessment of High-Risk Symptoms. The (SOPS) and its companion Structured 
Interview for Prodromal Symptoms or (SIPS) were developed by McGlashan and 
colleagues to assess symptoms for identifying prodromal states (McGlashan et al., 2010). 
The SOPS contains five items measuring positive symptoms (unusual thought content, 
suspiciousness, grandiosity, perceptual abnormalities, speech disorganization), six items 
measuring negative symptoms (social isolation, avolition, decreased expression of 
emotion, decreased experience of emotion, decreased ideational richness, decreased role 
functioning), four items measuring disorganization symptoms (odd appearance, bizarre 
thinking, poor focus/attention, poor hygiene), and four items measuring general 
symptoms (sleep disturbance, dysphoric mood, motor disturbance, decreased stress 
tolerance).  These symptoms are rated on a 7-point anchored scale ranging from 0 (not 
present) to 6 (psychotic or extreme intensity). According to Miller et al (2003), the SOPS 




The Schedule for Affective Disorders and Schizophrenia for School-Age 
Children, Epidemiologic Version. The K-SADS-E is a semi-structured interview that 
uses both child and parent interviews to diagnostically assess current and lifetime 
disorders such as affective, anxiety, behavioral, psychotic disorders, and substance use 
disorders (K-SADS-E; Orvaschel & Puig-Antich, 1994). Current episodes are rated on a 
severity scale and identified as mild, moderate, or severe and past episodes are rated as 
absent or present. Ratings are based on specific DSM-IV criteria for each disorder 
assessed (Ambrosini et al., 2000). The KSADS-E has been found to have good internal 
consistency of its scales, with reported Cronbach alpha coefficients between .51 and .75 
for its subscales (Ambrosini et al., 2000).  
The Structured Interview for the Diagnosis of Personality for DSM- IV. The 
SIDP-IV assessed personality traits/disorders (SIDP-IV; Pfohl, Blum, &Zimmerman, 
1995). This semi-structured interview assesses the diagnostic criteria for the 10 
personality disorders in the DSM-IV (i.e. paranoid, schizoid, schizotypal, borderline, 
narcissistic, histrionic, antisocial, avoidant, dependent, and obsessive-compulsive).  
Questions are arranged by themes instead of by disorders (e.g. interpersonal relationships, 
emotions, interests) and each criterion is rated on a scale from 0 to 3. Each item 
represents a specific symptom or trait associated with a disorder and is rated as 0 (not 
present or limited to rare isolated  examples), 1 (subthreshold-some evidence of the trait 
but is not sufficiently pervasive or severe to consider the criterion present), 2 (present-
criterion is clearly present (at least 50% of the time) for most of the last 2 years), or 3 
(strongly present- criterion is associated with subjective  distress or some impairment in 
social or occupational functioning or intimate relationships.) In order to receive a 
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diagnosis for a personality disorder, the participant must meet the required number of 
symptoms for that particular personality disorder at either the “present” or “strongly 
present” level. The SIDP-IV has good internal consistency, with a Cronbach alpha 
coefficient of at least 0.70 for it’s scales (Jane et al., 2006).  
Global Functioning: Social (GF:Social) and Role (GF:Role) scales. Social and 
role functioning were assessed using these measures. These scales account for age and 
phase of illness and detect functional changes over time. Unlike other scales, these scales 
avoid confounding functioning with psychiatric symptoms. The GF: Social scale assesses 
peer relationships, peer conflict, age-appropriate intimate relationships, and involvement 
with family members. The GF: Role scale rates performance level and amount of support 
needed in one’s specific role (i.e., school or work). For both scales, scores range from 1 
(extreme dysfunction) to 10 (superior functioning) and anchors are provided at each 
increment. Ratings for each of the scales were obtained from clinical information based 
on clinician reports and interviews (Cornblatt et al., 2007). The Global Functioning: 
Social (GF:Social) and Role (GF:Role) scales have excellent internal consistency with a 
Cronbach’s alpha coefficient of above 0.80 for both scales (Cornblatt et al., 2007).  
 Research design and analysis. All statistical procedures were calculated using 
SPSS version 22.  
 Missing data. Before performing any analyses, the categorical and continuous 
variables were checked for any errors that may fall outside of the possible range of 
values, as this may distort future analyses and were also checked for missing values. Data 
were missing for NAPLS IQ (7.7%) and for  Sum total of negative symptoms (13.5%).  It 
was determined that the data was missing completely at random and expectation 
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maximization was imputed to assign missing values (Dempster, Laird, N., & Rubin, 
1977). 
 Preliminary analysis. Descriptive statistics were calculated for basic 
demographic comparisons on gender, age, IQ, and race between RAP subgroups (CHR-, 
CHR+). Chi squares were computed for categorical variables (gender and race) and 
ANOVAs for continuous variables (age and IQ).  
  Statistical Analyses. Axis I disorders will be analyzed individually and collapsed 
into the following summary categories: mood disorders, anxiety disorders, substance use 
disorders, and other disorders. Axis II disorders will be collapsed into 3 clusters (Cluster 
A, Cluster B, Cluster C) in addition to being examined as individual personality disorders 
(10 disorders).  
For Hypothesis 1, Chi-square analyses will be used to compare the prevalence 
rates for the above-mentioned groupings of Axis I and Axis II disorders at baseline 
between the prodromal groups (CHR- and CHR+; Hypothesis 1).  
 For Hypothesis 2, the association between psychiatric disorders (mood, anxiety, 
substance use, and attention-deficit and disruptive behavior disorders ), functioning 
(social and role functioning), and attenuated symptoms (positive and negative symptoms) 
will be tested by evaluating correlations between these variables for CHR- and CHR+ 
groups separately. If significant correlations are found between the variables, then this 
will be followed up with ANOVAs to determine if there are differences in functioning 
(social or role functioning) based on psychiatric disorders and by group status 
(CHR+/CHR-). For these analyses, independent variables (psychiatric disorders and CHR 
group status) and dependent variables (social/role functioning, attenuated symptoms) will 
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be entered into the models to determine if there are significant differences in functioning 
and attenuated symptom presentation based on type of psychiatric disorder and CHR 
group status.  To reduce Type 1 Error, the critical p value will be adjusted to account for 
multiple comparisons (p < 0.01). 
For Hypothesis 3, we will evaluate the stability of Axis I and II disorders, by 
following the methodological approach illustrated by Lin et al. (2015).  To examine the 
course of the Axis I and II disorders, participants will be organized into four different 
categories. If the disorder was not present at baseline and follow-up, it will be categorized 
as “not present.” If the disorder was present at baseline and follow-up, it will be classified 
as “persistent/recurrent”.  Disorders that were present at baseline but absent at follow-up 
will be labeled “remitted” and disorders that were present at follow-up but absent at 
baseline will be classified as “incident” cases.  The frequencies of each category will be 
obtained for CHR- and CHR+ groups separately and compared by psychiatric disorders.  
For Hypothesis 4, we will assess predictors of conversion by first examining the 
association between conversion and the SOPS scale (positive symptoms, negative 
symptoms, disorganized symptoms, and general symptoms) by calculating correlation 
coefficients. The coefficients found to be significant at the p<.01 level would then be 
entered into the binary logistic regression model in conjunction with Axis I disorders 
(mood, anxiety, substance use, attention-deficit and disruptive behavior disorders) to 









Chapter 4: Results 
 
This chapter offers an overview of the results of preliminary analyses such as 
descriptive statistics of the CHR+ and CHR- groups. It also reports the findings of chi-
square analyses, ANOVAs, and regression analyses used to analyze clinical and 
functional outcomes for the two high-risk groups.   
Demographics and Clinical Characteristics 
Demographic and clinical characteristic information for the CHR subgroups are  
presented in Tables 1.1, 1.2. There were one hundred and fifty-six participants in this 
sample (110 males and 46 females). Frequencies were obtained assessing group 
differences based on gender and ethnicity. Results indicated that males were a larger 
proportion of this sample (70.5%) compared to females (29.5%).  When considering 
CHR group status for demographics, the CHR+ subgroup consisted of 65 males (64.4%) 
and 36 females (35.6%). In the CHR- group, 45 participants identified as male (81.8%) 
and 10 (18.2%) identified as female. Significant differences on gender were found at the 
.05 level F (1,154)=5.334, p= .022.  In terms of ethnicity, participants described 
themselves as mostly White (n = 122, 78.2%), Black (n =14, 9.0%), Asian (n =14, 9.0%), 
and Other/Mixed (n =6, 3.8%) and there were no significant differences found for 
ethnicity.  
ANOVAS were performed to compare the differences in age, IQ, total positive 
symptoms, total negative symptoms, total disorganized symptoms, total generalized 
symptoms, social functioning, and role functioning between the high-risk groups. 
Participants were between the ages of 12 and 22 (M = 15.97, SD = 2.14).  No significant 
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differences were found for age     F (1,154)=.589, p= .444 or IQ  F (1,142) = .224, p 
=.637 between the CHR subgroups.  
Participants completed the SOPS which measured total positive, negative, 
disorganized, and general symptoms. Generally, there was a trend of CHR+ participants 
scoring higher compared to CHR- participants on these scales. Significant differences 
were found for the report of positive F (1,154)=150.482, p=.000 and negative symptoms 
F (1,154)=8.659, p= .004. These results are expected given that assignment to the CHR 
groups are based on the presence of attenuated positive and negative symptoms. There 
were also significant differences in the report of disorganized symptoms at the .05 level  
F (1,154)=.414, p= .004. 
In assessing functioning between the two RAP subgroups, significant differences 
were found for social functioning F (1,154)=7.991, p=.005 but not for role functioning  













Table 1.1  





Gender   
    Male 110 70.5 
    Female 46 29.5 
Ethnicity    
    White 122 78.2 
    Black 14 9.0 
    Asian 14 9.0 
    Other/Mixed 6 3.8 
 
 
Table 1.2  







Age 16.07 ± 2.17 15.79 ± 2.09 .589 .444 
Gender, N(%)   5.334 .022* 
    Female 36 (35.6%) 10 (18.2%)   
    Male 65 (64.4%) 45 (81.8%)   
Ethnicity, N (%)   3.410 .067 
    Caucasian 81 (80.2%) 41 (74.5%)   
    Black 11 (10.9%) 3 (5.5%)   
    Asian 7 (6.9%) 7 (12.7%)   
    Other/Mixed 2 (2.0%) 4 (7.3%)   





SOPS Total Positive 8.85 ± 3.85 1.98 ± 2.09 150.482 .000** 
SOPS Total Negative 12.83 ± 5.42 15.55 ± 5.70 8.659 .004** 
SOPS Total 
Disorganized 
5.78 ±3.50 4.42 ± 3.51 5.414 .021* 
SOPS Total General 8.49 ±3.87 4.42 ± 3.51 2.209 .139 
Social Functioning 6.03±1.43 5.40± 1.12 7.991 .005** 
Role Functioning 5.55±2.03 5.35± 2.50 .320 .573 
     
**p  is significant at the 0.01 level  





Chi-square tests of independence were used to compare the prevalence rates of 
psychiatric disorders between the high-risk groups (CHR- and CHR+) at baseline.  To 
perform these analyses, Axis I disorders were collapsed into the following categories: 
mood disorders, anxiety disorders, substance use disorders, and attention-deficit and 
disruptive behavior disorders. Personality disorders were collapsed into 3 clusters 
(Cluster A, Cluster B, Cluster C) in addition to being examined as individual personality 
disorders (paranoid, schizoid, schizotypal, antisocial, borderline, histrionic, narcissistic, 
avoidant, dependent, and obsessive compulsive).  
Chi-square analyses were performed to assess the relationship between high-risk 
status (CHR + and CHR-) and mood disorders, anxiety disorders, substance use 
disorders, attention-deficit and disruptive behavior disorders, and personality disorders. 
The Fisher’s exact test was used to determine associations between the variables as one 
or more expected cell counts in the crosstabulations were less than five (Sprent et al., 
2011).  As displayed in Table 2.1, chi-square analyses revealed no significant differences 
in the proportion of high-risk participants who report mood, anxiety, substance use 
disorders, at baseline. As seen in Table 2.2, significant differences were found in 
participants who met criteria for paranoid personality disorder x2 (1, n=155) = 6.954, p 
=.008, schizoid personality disorder x2 (1, n =155)= 7.650, p=.006, and borderline 
personality x2 (1, n= 155)= 6.330, p=.009. CHR- participants were more likely to endorse 
schizoid personality disorder and CHR+ participants were more likely to report paranoid 
personality disorder and borderline personality disorder.  
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 As seen in Table 2.1, a large proportion of CHR+ and CHR- participants reported 
mood or anxiety disorders at baseline, 79.2% and 78.2 respectively. Additionally, when 
diagnoses are examined separately, 62.4% of CHR+ participants and 54.5% of CHR- 
participants met criteria for a mood disorder at baseline. Likewise, 54.5% of CHR+ 
participants and 45.5% of CHR- participants reported an anxiety disorder at baseline.   
Lowest proportions among high-risk participants were reported for substance use, 8.9% 
for CHR+ and 3.6% for CHR- participants. ADHD disorders were endorsed by CHR 
participants, with 33.7% in the CHR+ subgroup and 25.5% in the CHR-group. As for 
personality disorders, which are displayed in Table 2.2, 45.5% of CHR+ and 51.9% of 
CHR- participants did not meet criteria for an Axis II disorder. Among CHR- participants 
there was also a similarity in presentation of Cluster A and C personality disorders 
(22.2%). Generally, a larger proportion of CHR+ participants endorsed personality 
disorders compared to CHR- participants.  
The results indicate that there are differences in Axis II presentation, therefore 
partially supporting Hypothesis I. This further supports monitoring symptoms over time 










Table 2.1  
Prevalence Rates of Axis I Disorders at Baseline 
 
a No participants reported Bipolar Spectrum Disorder at baseline     
 **p is significant at the .01 level 
 




χ2 Fisher exact p-
value 
No Axis I Disorder 3(3.0) 4(7.3) 1.538 .243 
    
Mood and Anxiety Disorders 
Any Mood Disorder 63 (62.4) 30 (54.5) .907 .341 
    Major Depressive Disorder 44 (43.6) 16 (21.2) 3.152 .087 
    Dysthymic Disorder 6 (5.9) 4 (7.3) .105 .742 
    Bipolar Spectrum Disordera 









Any Anxiety Disorder 55 (54.5) 25 (45.5) 1.155 .317 
    Agoraphobia 2 (2.0) 0 (0.0) 1.103 .541 
    GAD 12 (10.4) 4 (7.3) .822 .422 
    OCD 









    PTSD 3 (3.0) 1 (1.8) .189 1.000 
    Social Phobia 23 (22.8) 19 (34.5) 2.509 .132 
    Specific Phobia  9 (8.9) 4 (7.3) .125 1.000 
    Other Anxiety Disorder 13 (12.9) 2 (3.6) 3.494 .087 
Any mood or anxiety                    
    Disorder 
80(79.2) 43 (78.2) .022 1.000 
Substance Disorders 
 Any substance Disorder 9 (8.9) 2 (3.6) 1.512 .330 
    Alcohol Disorder 2 (2.0) 0 (0.0) 1.103 .541 
    Cannabis Disorder 
    Cocaine Disorder 













    Nicotine Disorder 1 (1.0) 0 (0.0) .548 1.000 
    Polysubstance use Disorder 1 (1.0) 0 (0.0) .548 .461 
Other Disorders 
ADHD 34(33.7) 14(25.5) 1.126 .289 
Conduct Disorder 3(3.0) 2 (3.6) .051 .821 
Disruptive Behavioral         
    Disorder NOS 
1(1.0) 0 (0) .548 .459 
Oppositional Defiant Disorder 31(30.7) 9 (16.4) 3.835 .050 
Adjustment Disorder 3 (3.0) 3 (5.5) .594 .441 
Intermittent Explosive     
    Disorder 
1 (1.0) 1 (1.8) .193 .660 
Learning Disorder 5 (5.0) 5 (9.1) 1.018 .313 
Developmental Disorder 5 (5.0) 3 (5.5) .019 .892 
Tic Disorder 1 (1.0) 1(1.8) .193 .660 
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Table 2.2  
 
Prevalence Rates of Axis II Disorders at Baseline  
 





2 Fisher exact p-value 
No Axis II 
disorder 
46 (45.5) 28 (51.9) .561 .502 
 Cluster A 25 (24.8) 12(22.2) .124 .844 
    Paranoid PD 12 (11.9) 0 (0.0) 6.954 .009** 
    Schizoid PD 7 (6.9) 12 (22.2) 7.650 .009** 
   Schizotypal PD 11 (10.9) 1 (1.9) 4.025 .058 
Cluster B 11(10.9) 1(1.9) 4.025 .058 
    Antisocial PDa 0 (0.0) 0 (0.0) - - 
    Borderline PD 11 (10.9) 0 (0.0) 6.330 .009** 
    Histrionic PDb 0 (0.0) 0 (0.0) - - 
    Narcissistic PD 0 (0.0) 1(1.9) .102 .348 
Cluster C 32 (31.7) 12(22.2) 1.549 .263 
    Avoidant PD 29 (28.7) 12 (22.2) .762 .447 
    Dependent PD 2 (2.0) 0 (0.0) 1.083 .543 
    Obsessive 
Compulsive PD 
3(3.0) 0(0.0) 1.636 .552 
 
a No participants reported Histrionic PD diagnoses at baseline 
b No participants reported Antisocial PD diagnoses at baseline 
**p is significant at the 0.01 level  
 
Hypothesis 2 
 Correlation analyses and ANOVAS were conducted to determine if there are 
differences in functioning or attenuated symptom presentation by psychiatric disorder and 
CHR group status. Point biserial correlation coefficients were first performed to 
determine the relationships between psychiatric disorders, attenuated positive/negative 
symptoms, and social/role functioning for each of the high-risk groups (CHR+ and CHR-
). For the CHR+ subgroup, moderate correlations were found between Cluster A 
Personality Disorder and total positive symptoms (r = .268, n=101, p< .01), total 
negative symptoms (r = .330, n = 101, p<.01), and social functioning (r = -.318, n= 101, 
p <.01).  For the CHR- subgroup, there was a moderate positive correlation between 
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Cluster A personality disorder and total negative symptoms (r=.378, n=54, p<.001) and 
a strong negative correlation with social functioning (r=-.557, n=54, p<.001). There was 
also a moderate, negative correlation between mood and role functioning ( r= -.404, n= 
55, p<.01).  
For the CHR+ subgroup there were a few other significant correlations that were 
obtained at the p<.01 level although not part of our research aims such as cluster C and 
anxiety (r=.452, n =101, p<.01), social functioning and total negative symptoms (r=-
.501, n=101, p<.01), role functioning and total negative symptoms (r=-.439, n=101, 
p<.01). For the CHR- subgroup there were moderate to strong correlations obtained 
between Cluster C and anxiety (r=.576, n=54, p<.01) and role functioning and total 
negative symptoms (r=-.416, n=54, p<.01).   
Although these analyses are only focusing on significant correlations at the .01 
level, it is noteworthy that there are several significant correlations at the .05 level for 
CHR+ participants. These include small correlations between mood disorders and Cluster 
B personality disorders (r=.206, n=101, p<.01) and substance disorders and social 
functioning (r=.237, n=101, p<.01). Small, negative correlations were found between 
anxiety and attention-deficit and disruptive behavior disorders (r=-.202, n=101, p<.01), 
Cluster A personality disorders and role functioning (r=.203, n=101, p<.01), and Cluster 
C personality disorder and social functioning (r=-.253, n=101, p<.01). See Tables 3.1, 
3.2.  
 Overall, it appears that there are similarities in the presentation of Cluster A 
personality disorder among the CHR subgroups with significant associations between 
total negative and social functioning for both CHR+ and CHR- participants. Additionally, 
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significant associations were found between Cluster A personality disorder and total 
positive symptoms for the CHR+ subgroup and between mood disorder and role 
functioning. 
 After determining significant associations between attenuated positive and 
negative symptoms and functioning for Cluster A personality disorders and mood 
disorders, additional analyses were conducted using ANOVAS to further explore if there 
are differences in functioning or attenuated symptoms by disorder (Cluster A personality 
disorder or mood disorder) or by CHR group status (CHR+, CHR-). These results 
confirmed that role functioning has an impact on mood disorders F (1,53)=10.337, 
p=.002 for the CHR-subgroup. Additionally, these follow-up analyses confirmed that 
attenuated positive symptoms F (1,99)=7.632, p=.007,  negative symptoms 
F(1,99)=12.060, p=.000, and social functioning F (1,99)=11.136, p=.001 have an impact 
on Cluster A personality disorders for the CHR+ subgroup. Similarly, for the CHR-
subgroup attenuated negative symptoms F (1,53)= 8.674 p=.005 and social functioning F 
(1,53)=23.424, p=.000 were found to also have an impact on  Cluster A personality 
disorder presentation.  
These results partially support our hypothesis, as mood disorders were associated 
with lower role functioning and Cluster A personality disorders were associated with 







Table 3.1  
 Correlation Matrix for Clinical and Functional Characteristics in CHR + subgroup  
 






CA  CB  CC  Pos Neg Soc Role 
Mood 
 
---           
Anxiety 
 
.152 ---          
Substance 
 
.099 -.063 ---         
Behavioral 
 
-.064 -.202* .065 ---        
Cluster A PD .019 -.074 -.099 -.144 ---       
Cluster B PD .206* .192 .114 -.077 .020 ---      
Cluster C PD .177 .452** -.064 -.131 .152 .172 ---     
Total Pos 
 
-.057 .125 -.024 -.107 .268** .188 .176 ---    
Total Neg 
 
.114 -.013 .032 -.004 .330** -.045 .160 .046 ---   
Social Func 
 
.002 -.121 .237* -.024 -.318** .015 -.253* -.086 -.501** ---  
Role Func 
 
.011 .054 -.137 -.154 -.203* -.064 -.081 -.056 -.439** .187 --- 
 
**Correlation coefficient is significant at the 0.01 level  
*Correlation is significant at the 0.05 level  
 
 
Table 3.2   
 
Correlation Matrix for Clinical and Functional Characteristics in CHR - subgroup  
 






CA  CB  CC  Pos Neg Soc Role 
Mood   
 
---           
Anxiety 
 
-.120 ---          
Substance 
 
-.213 .018 ---         
Behavioral 
 
.100 -.247 .018 ---        
Cluster A 
PD 
-.060 -.228 -.105 -.050 ---       
Cluster B 
PD 
.123 -.128 -.027 -.128 -.073 ---      
Cluster C 
PD  
.030 .576** -.105 -.050 -.071 -.073 ---     
Total Pos  
 
.133 -.080 -.045 .043 .041 .207 .150 ---    
Total Neg 
 
.257 -.052 -.043 -.104 .378** .007 -.003 .433 ---   
Social Func 
 
.066 -.165 .018 .132 -.557** -.176 -.052 .051 -.453** ---  
Role Func 
 
-.404** .035 .130 -.187 .004 -.128 .112 -.102 -.416** -.090 --- 
 
**Correlation coefficient is significant at the 0.01 level  






Association between Mood Disorders and High-Risk Symptoms and Functioning  
 
 
**p is significant at the 0.01 level 
 
 
Table 3.4  
 





**p is significant at the 0.01 level 
 
Predictor  df F sig 
CHR+     
     
Total Positive  (1,99) .320 .573 
Total Negative  (1,99) 1.299 .257 
Social Functioning  (1,99) .000 .985 
Role Functioning  (1,99) .012 .915 
     
CHR-     
     
Total Positive  (1,53) .959 .332 
Total Negative  (1,53) 3.733 .059 
Social Functioning   (1,53) .232 .632 
Role Functioning   (1,53) 10.337 .002** 
     
Predictor  df F sig 
CHR+     
     
Total Positive  (1,99) 7.632 .007** 
Total Negative  (1,99) 12.060 .000** 
Social Functioning  (1,99) 11.136 .001** 
Role Functioning  (1,99) 4.240 .042 
     
CHR-     
     
Total Positive  (1,53) .088 .768 
Total Negative  (1,53) 8.674 .005** 
Social Functioning   (1,53) 23.424 .000** 
Role Functioning   (1,53) .001 .977 




Table 4.1 displays the course of psychiatric disorders for high- risk groups by 
presenting frequencies of baseline, remission, incidence, persistence/recurrence, and 
absence of Axis I and Axis II disorders. As seen in Table 4.1, all high-risk participants, 
had a disorder present at baseline. For CHR+ participants, 34.5% had a disorder that 
remitted, and 75.9%  had a disorder that was persistent, and 44.8% had a new onset of a 
disorder. As observed in CHR- participants, 38.5% had a disorder that remitted, 100% 
had a disorder that was persistent/recurrent, and 23.1% had a new onset of a disorder.  
Mood disorders. 58.6% of CHR+ participants had a mood disorder at baseline, 
10.3% had a mood disorder that remitted and 48.3% had a mood disorder that was 
persistent. 31.0% of CHR+ participants never had a mood disorder and 10.3% developed 
a mood disorder. For CHR- participants, 30.8% had a mood disorder present at baseline, 
23.1% had a mood disorder that was persistent, developed, or never present.  
Anxiety disorders.  For those participants with anxiety disorders, 44.8% of CHR+ 
participants reported an anxiety disorder at baseline, 6.9% developed an anxiety disorder 
and 48.3% never had an anxiety disorder. In comparison, for CHR- participants, 53.8% 
had an anxiety disorder at baseline, 7.7% had an anxiety disorder that remitted, 46.2% 
had an anxiety disorder that was persistent and never had an anxiety disorder. 
Substance Use.  For substance use, 6.9% of CHR+ and 15.4% of CHR-
participants had a substance use disorder that was present at baseline. 6.9% of CHR+ 
participants had a substance use disorder that remitted, 0% had a substance use disorder 
that was persistent, 93.1% of participants never had a substance use disorder and 3.4% 
developed a substance use disorder. For CHR- participants, 0% had a substance use 
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disorder that remitted or developed, 15.4% had a substance use disorder that was 
persistent, 84.6% never had a substance use disorder. Also, substance use disorders were 
more likely to be never present at baseline or follow-up.  
Personality disorders.  Of all CHR+ participants, 44.8% of participants had a 
personality disorder present at baseline, 10.3% had a personality disorder that remitted, 
61.5% had a personality disorder that was persistent, 13.8% developed a personality 
disorder and 41.4% never had a personality disorder. In comparison, 61.5% of CHR- 
participants had a personality disorder at baseline, 7.7% had a personality disorder that 
remitted, 61.5% had a personality disorder that was persistent/recurrent, 0% developed a 
personality disorder, and 30.8% never had a personality disorder.  
Attention-deficit and disruptive behavior disorders. Of all high-risk participants, 
51.7% of CHR+ subjects and 30.8% of CHR- subjects had an attention-deficit and 
disruptive behavior disorder present at baseline. For CHR+ participants, 17.2% had an 
attention-deficit and disruptive behavior disorder that remitted, and 34.5% had disorders  
that were persistent, 3.4% developed one of these types of disorders, and for 37.9% of 
participants, attention-deficit and disruptive behavior disorders were not present at 
baseline or follow-up.  
Additionally, high-risk participants developed psychotic disorders at similar rates, 
with 20.7% of CHR+ participants and 23.1% of CHR- participants reporting psychosis at 
follow-up.  
  It was hypothesized that mood and anxiety disorders would be the most 
persistent/recurrent but our analyses revealed that these disorders in addition to 
personality disorders and attention-deficit and disruptive behavior disorders were also 
61 
 
persistent, therefore rejecting our hypothesis. It is noteworthy that for CHR- participants, 
























Table 4.1  
The course of Axis I and Axis II Disorders 
 




Present at baseline   
    Any disorder 29 (100.0) 13 (100.0) 
    Any mood disorder 17 (58.6) 4 (30.8) 
    Any anxiety disorder 13 (44.8) 7 (53.8) 
    Any substance use disorder 2 (6.9) 2 (15.4) 
    Any personality disorder 13 (44.8) 8 (61.5) 
    Any attention-deficit and disruptive            
          behavior disorder         
15 (51.7) 4 (30.8) 
Remitted   
    Any disorder 10 (34.5) 5 (38.5) 
    Any mood disorder 3 (10.3) 2 (15.4) 
    Any anxiety disorder 3 (10.3) 1 (7.7) 
    Any substance use disorder 2 (6.9) 0 (0.0) 
    Any personality disorder 3 (10.3) 1 (7.7) 
    Any attention-deficit and disruptive            
          behavior disorder         
5 (17.2) 1 (7.7) 
Incident   
    Any disorder 13 (44.8) 3 (23.1) 
    Any mood disorder 3 (10.3) 3 (23.1) 
    Any anxiety disorder  2 (6.9) 0 (0.0) 
    Any substance use disorder 1 (3.4) 0 (0.0) 
    Any personality disorder 4 (13.8) 0 (0.0) 
    Any attention-deficit and disruptive            
          behavior disorder         
1 (3.4) 0 (0.0) 
   Any Psychotic disorder 6 (20.7) 3 (23.1) 
Persistent or Recurrent   
    Any disorder 22 (75.9) 13 (100.0) 
    Any mood disorder 14 (48.3) 3 (23.1) 
    Any anxiety disorder 10 (34.5) 6 (46.2) 
    Any substance use disorder 0 (0.0) 2 (15.4) 
    Any personality disorder 10 (34.5) 8 (61.5) 
    Any attention-deficit and disruptive            
          behavior disorder         
10 (34.5) 3 (23.1) 
Never present   
    Any disorder 0 (0.0) 0 (0.0) 
    Any mood disorder 9 (31.0) 7 (53.8) 
    Any anxiety disorder 14 (48.3) 6 (46.2) 
    Any substance use disorder 27 (93.1) 11(84.6) 
    Any personality disorder 12 (41.4) 4 (30.8) 
    Any attention-deficit and disruptive            
          behavior disorder         






Correlation analyses were performed to evaluate the association between 
conversion and types of symptoms, revealing positive associations between total positive 
symptoms on the SIPS and conversion (r =.26, p< .001). See Table 5.1.  
 A binary logistic regression was performed to assess the impact of a number of 
factors on the likelihood that participants would convert to psychosis. First data were 
checked to ensure that none of the assumptions were violated (sample size, 
multicollinearity, and outliers). Independent variables for the model included positive 
symptoms, Axis I disorders(baseline mood, baseline anxiety, baseline substance use and 
baseline attention-deficit and disruptive behavior disorders).  The full model containing 
all the predictors was statistically significant, χ2 (5, N=101)=14.92, p <.05,  indicating 
that the model was able to distinguish between respondents who converted and those who 
did not convert.  The model as a whole explained between 13.7% (Cox and Snell R 
square) and 24.2% (Nagelkerke R squared) of the variance in conversion status, and 
correctly classified 88.1% of cases.  As shown in Table 5.2, total positive symptoms was 
the strongest predictor of conversion, with an odds ratio of  1.208. Of the baseline 
psychiatric disorders entered into the regression, only the absence of a baseline mood 
disorder was a significant predictor of conversion with an odds ratio of .225. Our 
hypothesis is partially supported as positive symptoms were found to be the strongest 
predictor of conversion, however  the presence of a mood disorder predicted non-
conversion to psychosis which was unexpected.  
Chi-square analysis were then performed to assess the relationship between  Axis 
I disorder and conversion status which are all categorical variables.  These results were 
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statistically significant, revealing that only 35.3% of individuals with mood disorders at 
baseline converted to psychosis. This analysis further supported that there is a significant 





Table 5.1  
 
Correlations between Conversion and SOPS 
 






























































**Correlation is significant at the 0.01 level  











 Logistic Regression Predicting Likelihood of Conversion 
 β S.E. Wald df p Odds 
Ratio 
95% CI for 
Odds Ratio 








































-.786 .743 1.118 1 .290 .456 .106 1.956 
Constant -.2689 1.060 6.431 1 .011 .068   
 





















2 Fisher exact p-
value 
Mood disorder 6 (35.3%) 87 (62.6%) 4.688 .038* 
Anxiety disorder 9 (52.9%)  71 (51.1%) .021 1.000 




6 (35.3%) 76 (54.7%) 2.282 .197 
 
*p is significant at 0.05 
level 
 
    
     






























Chapter 5: Discussion 
 
 
 This current study assessed the progression of Axis I and Axis II disorders in 
subjects who participated in the first phase of the Recognition and Prevention (RAP) 
Program from 2000-2006. This study used the RAP model to examine the rates of 
comorbidity, the development of psychiatric disorders, the relationship between 
psychiatric disorders and functioning, and the clinical predictors of conversion in a CHR 
sample consisting of participants who were in high- risk groups (CHR + and CHR-).  
Prevalence Rates of Axis I and Axis II Disorders at Baseline  
Our first hypothesis was partially confirmed and there essentially were no 
differences in rates of comorbid psychiatric disorders between the CHR+ and CHR- 
groups. However, there are some exceptions and noteworthy findings regarding the 
presentation of personality disorders. As mentioned previously, there is increasing 
evidence that personality disorder pathology is present in individuals who are high risk 
for developing psychosis ( Klosterkötter et al., 2001; Lim et al., 2018;  Ruhrmann et al., 
2010; Ryan et al., 2015). In exploring the association between personality pathology and 
high-risk status, this current study found that there are significant differences between the 
high-risk groups in the presentation of borderline personality disorders, and paranoid 
personality disorders, and schizoid personality disorders.  Results from this study convey 
that CHR- participants are more likely to meet criteria for schizoid personality disorder 
and CHR+ subjects are more likely to meet criteria for paranoid personality disorder and 
borderline personality disorder.  
Regarding schizoid personality disorder, the symptoms are similar to the 
attenuated negative symptoms associated with the CHR- subgroup. In order to meet 
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criteria for the CHR-subgroup, participants must endorse at least one of the following 
negative symptoms with a score of 3 or above: social anhedonia, avolition, expression of 
emotion, experience of emotions and self, ideational richness, and occupational 
functioning (Miller et al., 1999). Similarly, individuals with schizoid personality features 
present with interpersonal, social, and affective deficits which are also consistent with the 
features of negative symptoms. Those who meet criteria for this disorder appear to isolate 
from others, display restricted range of emotional expression marked by flattened affect 
and appear detached (American Psychiatric Association, 2000; Esterberg et al., 2010). 
Earlier studies have confirmed the link between schizoid personality symptoms and 
negative symptoms (Cannon et al., 1990; Cuesta et al., 1999; Cuesta et al, 2002). Peralta 
et al. (1991) explained that “the negative schizophrenic symptoms are merely the 
persistence or exacerbation of schizoid traits present prior to the emergence of psychotic 
symptoms”, (p.338). This overlap in symptomatology explains why participants in the 
CHR- subgroup were more likely to present with schizoid personality disorder and 
further supports that symptoms associated with schizoid traits are early manifestations of 
negative symptoms.  
Subjects in the CHR+ group were more likely to meet criteria for paranoid 
personality disorder which is consistent with the positive symptom classification of this 
disorder. For CHR- participants to meet criteria for paranoid personality disorder would 
imply that subjects endorsed at least one attenuated positive symptom which by definition 
conflicts with the CHR- subgroup category (Lencz et al., 2004). Attenuated positive 
symptoms that overlap with paranoid personality disorder include suspiciousness and 
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mistrust of others, and unusual thought content (American Psychiatric Association, 2013; 
Esterberg et al., 2010; Miller et al., 1999).  
Results also indicated that participants in the CHR+ subgroup were more likely to 
endorse borderline personality disorder compared to those in the CHR-subgroup. As 
stated previously, there is shared symptom presentation between borderline personality 
disorder and attenuated positive symptoms which may make it challenging to distinguish 
between personality pathology and psychosis pathology (Ryan et al., 2017; Thompson et 
al., 2012). A fairly recent study  conducted by Paust and colleagues in 2019 also 
confirmed this position. This study examined borderline personality symptoms and 
transition to psychosis in a sample of at-risk youth. Borderline personality dimensions 
were assessed using the Borderline Symptom Checklist (BSL-95) and results supported 
that positive symptoms such as unusual thought content, suspiciousness/persecutory 
ideas, and hallucinations were strongly correlated with BSL scores (Paust et al., 2019) 
Overall, the overlap in personality pathology symptoms with attenuated positive 
or negative symptoms suggests that additional longitudinal studies are necessary to 
clarify the relationship over the long term, especially for those who do not develop 
psychosis. The latter group of non-converters may represent false positives for psychosis 
who were inaccurately classified as high risk for psychosis. Furthermore, it may be 
beneficial to screen individuals who present with paranoid, schizoid, and borderline 
personality pathology for high-risk status given that some studies (although not this one) 
find an association between these disorders and psychosis. Lastly, these findings have 
important treatment implications as interventions will need to address all comorbidities 
and could inform specific treatment interventions. 
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Additionally, there is evidence of an observed difference in the presentation of 
oppositional defiant disorder (ODD) x2 (1, n =155)= 3.835 p=.050,  between the CHR 
subgroups, as CHR+ participants (30.7%) were more likely to meet criteria for ODD 
compared to CHR- participants (16.4%). The research specifically on ODD and high-risk 
is scarce but there are a few studies that do report prevalence rates of ODD between 2-5% 
(Addington et al., 2017; Preda et al., 2002;  Staddard et al., 2010). A recent longitudinal 
study, assessing psychiatric diagnoses in children and adolescents from age 8 to 13 
determined that ODD was associated with psychotic experiences in adults (Siebald et al., 
2016). While there appears to be some association between ODD and high-risk for 
psychosis, additional studies may be able to elucidate the relationship between ODD and 
the CHR+ subgroup.  
Although no significant associations were found between high-risk subgroup and 
Axis 1 diagnoses, the chi-square analyses display frequencies offering exploratory 
information regarding baseline diagnoses presentation within the high-risk groups.  
Consistent with previous studies, mood and anxiety disorders were the most prevalent at 
baseline (Addington et al., 2011; Fusar-Poli et al., 2014; Lencz et al., 2004;  Lin et al., 
2015). For the CHR+ subgroup 62.4% of participants met criteria for a mood disorder, 
and 54.5% endorsed a mood disorder in the CHR- subgroup. These results are also 
consistent with previous findings that MDD is typically the most prevalent mood disorder 
diagnosis among CHR participants (Kline et al., 2018; Lin et al., 2015; Meyer et al., 
2005; Rosen et al., 2005). For anxiety disorders, 54.5% of subjects were in the CHR+ 
subgroup and 45.5% were in the CHR- subgroup.  There were similar rates for combined 
mood and anxiety disorders (CHR+ = 79.2, CHR- = 78.2). This is also consistent with the 
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current research that individuals at-risk for psychosis present with combined anxiety and 
affective disorders. Additionally, social phobia was the most prevalent anxiety disorder 
(CHR+ = 22.8%, CHR- = 34.5%) which supports previous studies (Hui et al., 2013; 
McAusland et al., 2017; Meyer et al., 2004).  
There is evidence to support that CHR subjects endorse attention-deficit and 
disruptive behavior disorders. For ADHD prevalence rates were (CHR+ = 33.7% and 
CHR- = 25.5%) and as stated previously for oppositional defiant disorder (CHR+ = 
30.7%  and CHR- =16.4%). While there were no significant differences in occurrence of 
attention-deficit and disruptive behavior disorders , these results support previous studies 
that they are present in the CHR population (Meyer et al., 2005; Thompson et al., 2015). 
Surprisingly, there were lower rates of substance use disorders observed in this sample 
(CHR + = 8.9%   and CHR- =3.6% compared to previous studies.  
Association Between Attenuated Positive and Negative Symptoms and Functioning 
in Axis I and Axis II disorders  
Our study supported previous findings that Cluster A personality disorders 
(paranoid, schizoid, schizotypal)  are associated with impaired social functioning 
(Fonseca-Pedrero et al., 2010; Henry et al., 2008; Oltmanns et al., 2002). These findings 
are expected as individuals who meet criteria for these disorders often present in a 
socially dysfunctional manner which deviates from the norm (Esterberg et al., 2010). 
Individuals with paranoid personality disorder may be considered odd or eccentric and 
may lack close relationships due to mistrust of others. Those who meet criteria for 
schizoid personality disorder may present with detachment from social relationships and 
restricted range in emotional expression. Lastly, individuals with schizotypal personality 
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disorder may lack a desire to form close interactions and may find it challenging trying to 
relate to others (American Psychological Association, 2000). Additional studies have 
found that individuals who meet criteria for Cluster A personality disorders also present 
with persistent decline in social functioning (Oltmanns et al., 2002; Seivewright et al., 
2004). These findings suggest that it is important to take into account social functioning 
when assessing personality pathology presentation.  
Cluster A personality disorders were found to be associated with attenuated 
negative symptoms for both the CHR- and CHR+ subgroups. Expectedly, for the CHR+ 
group, there was a significant correlation between attenuated positive symptoms. Cluster 
A personality disorders are grouped together by shared positive and negative traits. A 
possible explanation for the shared presentation in negative symptoms may be an overlap 
between the social anhedonia scale and social functioning. As explained by Pelletier-
Baldelli et al 2021 “it may be that reduced capacity to experience pleasure leads to 
diminished seeking out of interpersonal situations” (p. 101).  
Notably, significant moderate associations were also found between social functioning 
and negative symptoms for both subgroups. Negative symptoms have proven to be a 
determinant of social functioning based on previous studies. In a sample consisting of 
167 CHR individuals, Fulford et al (2013) showed that severity of negative symptoms 
was significantly predictive of social functioning at baseline and follow-up. Furthermore, 
another study found negative symptoms to be a mediator between social function and 
global neurocognition (Meyer et al., 2014). Schlosser and colleagues also found negative 
symptoms to be a significant predictor of social functioning above and beyond mood 
symptoms. Additionally, experiential negative symptoms such as avolition, anhedonia 
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were more predictive of social functioning in comparison to expressive symptoms 
(emotional expressivity and alogia) perhaps suggesting that avolition and anhedonia are 
important determinants of social functioning. Additionally, experiential negative 
symptoms were also found to be a mediator between expressive symptoms and social 
functioning (Schlosser et al. 2015). These results imply that it could be beneficial to 
create targeted social interventions for high-risk participants.  
Results also showed a strong association between Cluster C personality disorders 
and anxiety disorders which is supported by previous studies. As mentioned by Brandes 
& Bienvenu (2006), Cluster C is referred to as the ‘anxious cluster’ comprising of 
avoidant personality, dependent personality, and obsessive compulsive personality 
disorders. While anxiety disorders are co-occuring in individuals who meet criteria for 
personality disorders, the highest proportion appears to be among those with Cluster C 
personality disorders (Bienvenu, O. J., & Stein, M. B. (2003; Friborg et al., 2013; 
Sanderson et al. 1994).  
Lastly, in this study mood disorders were associated with lower role functioning 
for CHR- which is supported by previous research (Fulford et al. 2013). Specifically, 
depression was significantly associated with impairment in role functioning. When 
depression diagnoses was included in a regression analyses and negative symptoms were 
controlled, depression was found to be a significant predictor of social functioning. 
Therefore, additional studies need to be conducted to further evaluate the relationship 
between depression, negative symptoms, and functioning.  
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Course of Axis I and Axis II Disorders  
Our study replicated findings from Lin et al. (2015), supporting that mood and 
anxiety disorders are persistent and recurrent from baseline to follow-up in both CHR 
subgroups. For CHR+ participants 48.3% of mood disorders and 34.5% of anxiety 
disorders were persistent and recurrent. Among CHR-participants, 23.1% of mood 
disorders and 46.2% of anxiety disorders were persistent. Our findings also conveyed that 
personality disorders and attention-deficit and disruptive behavior disorders were also 
persistent among the subgroups. It was also surprising that substance use rates were 
rather low in this sample and was persistent in 15% of CHR- participants.  
In assessing high risk individuals, it would be imperative to continue to screen for 
psychiatric disorders in this population. We only had 42 individuals for these follow-up 
analyses and were underpowered to perform additional analyses. Further studies may be 
able to expand on this research and explore the impact the persistence of these disorders 
may have on response to treatment and early intervention strategies. Also, additional 
analyses may be able to make more meaningful interpretations about the course of 
diagnoses in these subgroups.  
Predictors of Conversion  
Expectedly, positive symptoms were found to be a strong predictor of conversion 
which is also consistent with previous studies. Yung et al. (2003) explored the duration of 
attenuated positive symptoms in CHR individuals and results demonstrated that a longer 
duration of these symptoms increased transition to psychosis. In another study, more 
severe positive symptoms were found to be predictors of conversion (Carrion et al 2016).  
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Although mood disorders were persistent in the RAP subgroups, it appears that 
the presence of mood disorders predicts non-conversion to psychosis. Thus, having a 
mood disorder appeared to be protective against psychosis, which likely indicates that 
mood disorders account for the CHR presentation rather than being true risk factors for 
psychosis. Further analyses on how mood disorders evolve during the other stages may 
help to clarify the role of mood disorders in this population.  
As mentioned previously, the RAP model has expanded to include CHR+ mod 
and also the SLPs. In a more recent study, Carrión et al (2017) evaluated the course of 
symptoms, differences in treatment outcomes, and conversion at different stages of the 
model. In this paper, the RAP model has been updated to highlight the range in symptom 
severity from moderate to severe for attenuated positive symptoms or the CHR+ stage. 
The updated model is as follows CHR-  CHR+Mod  CHR+Sev SLP.  CHR+Mod 
has a total positive symptom score of <10 and for CHR+Sev a total positive symptom 
score of ≥ 10.  (For the purposes of this study, we are using the previous 3-stage model). 
Results from this study indicate that risk for conversion is dependent on the entry point in 
the model, with CHR- stage showing the lowest risk of conversion of 5.9% and the 
highest symptom stability (70%). Whereas the SLP subgroup has the lowest symptom 
stability and the highest conversion rate of 49%. For the CHR+ moderate and severe 
subgroups, conversion rates were 28% and 11% respectively. The RAP staging model 
suggests that interventions should be more specific to target symptom severity. With that 
being said, individuals with more severe symptoms will be provided with more 
aggressive treatment options. In this study, subjects in the CHR- and CHR+Mod 
subgroups responded well to antidepressant medications, implying that antidepressants 
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may be particularly effective in earlier stages. The differences in symptom presentation, 
response to interventions, and conversion rates suggests that these subgroups are separate 
entities and should not be clustered together when exploring targeted interventions. See 
Figure 2. Additional studies could explore how disorders progress through these different 
stages and also help to clarify whether or not high-risk individuals may be at a higher risk 
of conversion compared to young adults who present with similar co-occurring disorders 
without the high-risk status (Albert et al., 2018).  
Strengths and Limitations  
 A major strength of this study was the long follow-up period which was 
instrumental in assessing outcomes over a longer period of time. A limitation of this 
study is the variability in follow-up times which revealed a smaller sample size and 
smaller sample size included in follow-up analyses. We suggest additional analyses with 
longer-term follow-up periods to hopefully replicate some of these findings and also 
further explore the progression of psychiatric disorders in the RAP subgroups.  
Conclusion 
 These findings provide implications for further research on the developmental 
course of symptoms for high-risk individuals. The comorbid rates and persistence over 
follow up of Axis I and Axis II disorders in the high-risk population suggests that there 
needs to be further screening of these individuals. Findings revealed that functioning and 
attenuated symptoms presentation vary in the subgroups. This research provides further 
information on factors that can be used to create targeted interventions for individuals 
who are in different stages of high-risk.  Additionally, since affective, anxiety, behavioral 
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concerns may be the impetus for seeking treatment, additional screening measures may 
help to explore developmental pathways that may impact the course of psychosis.  






































Figure 1. Recognition and Prevention (RAP) neurodevelopmental model (Repinted from 
















Figure 2.  Recognition and Prevention (RAP) model of progression of high-risk 
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